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During metastatic colonization, tumor cells must
establish a favorable microenvironment or niche that
will sustain their growth. However, both the temporal
and molecular details of this process remain poorly
understood. Here, we found that metastatic initiating
cells (MICs) exhibit a high capacity for lung fibroblast
activation as a result of Thrombospondin 2 (THBS2)
expression. Importantly, inhibiting the mesenchymal
phenotype of MICs by blocking the epithelial-to-
mesenchymal transition (EMT)-associated kinase
AXL reduces THBS2 secretion, niche-activating abil-
ity, and, consequently, metastatic competence. Sub-
sequently, disseminated metastatic cells revert to an
AXL-negative, more epithelial phenotype to prolifer-
ate and decrease the phosphorylation levels of TGF-
b-dependent SMAD2-3 in favor of BMP/SMAD1-5
signaling. Remarkably, newly activated fibroblasts
promote this transition. In summary, our data reveal
a crosstalk between cancer cells and their microenvi-
ronment whereby the EMT status initially triggers and
then is regulated by niche activation during metasta-
tic colonization.
INTRODUCTION
Solid epithelial tumors are complex structures in which associ-
ated stromal cells, including fibroblasts, support cancer cells.
During metastatic progression, cancer cells disseminate from
their tissue of origin to re-establish the tumor structure in distant
organs. Efficient metastasis requires the expression of specific
molecules, such as POSTN and TNC, within the local microenvi-
ronment (Malanchi et al., 2012; Oskarsson et al., 2011). There-
fore, a favorable microenvironment, or niche, is a crucial early
requirement for metastatic progression (Sleeman, 2012). How-2456 Cell Reports 13, 2456–2469, December 22, 2015 ª2015 The Auever, the factors that promote efficient metastatic niche activa-
tion remain poorly characterized.
Cancercellsdisplayheterogeneity in intrinsic tumorigenicpoten-
tial; only a small subset of cells within tumors retains the ability of
sustaining long-term growth (Hermann et al., 2007; Malanchi
etal., 2008)aswell as triggering relapses (Chenetal., 2012).Cancer
cells with the stem cell-like property of self-renewal can be defined
functionally as cancer-initiating cells (CICs) for their capacity to
elicit tumor growth. Moreover, metastatic initiating cells (MICs)
can be distinguished from the bulk of cancer cells for their ability
to establish metastasis. The functional assay for MICs involves
determining the extent to which single cells can grow in a foreign
tissueand ismorechallenging than theequivalent orthotopic trans-
plantation assay used to assess the ability of CICs to initiate tumor
growth. Although self-renewal ability is a common requirement for
the re-initiation of a cancer cellmass at either primary or secondary
sites, additional characteristics that discriminate MICs from CICs
have not been explored. MICs have been identified previously in
themouse breast cancer model wheremousemammary tumor vi-
rus promoter controls the expression of the polyomavirusmiddle T
antigen (MMTV-PyMT) (Malanchi et al., 2012). We hypothesized
that, in addition to intrinsic tumorigenic potential, MICs would
exhibit ahighercapacity for interactingwith their nichebyactivating
naive cells at distant sites (Malanchi, 2013).
One strategy adopted by carcinoma cells to disseminate from
theprimary tumormass is theactivationof thedevelopmental pro-
gram epithelial-to-mesenchymal transition (EMT). During EMT,
epithelial cells undergo a global change in cell architecture, lead-
ing to the loss of cell-cell adhesions in favor of cell-extracellular
matrix (ECM) interactions and cell migration (Thiery et al., 2009).
Notably, EMT modulations are not binary, but a graded range of
intermediate states exists. The process is initiated by the activa-
tion of the EMT core transcription factors (TFs) Snail, Zeb, and
Twist1 (Peinado et al., 2007), which drive epithelial cancer cells
to switch off the expression of epithelial markers such as the ad-
herens junction protein E-Cadherin and activate the expression of
mesenchymalmarkers such as Vimentin. The tyrosine kinaseAXL
is a downstream effector of the EMT program (Vuoriluoto et al.,thors
2011). EMT in breast cancer cells triggers an increase in AXL
expression, and inhibition of AXL reduces the invasive and tumor-
igenic behavior of cancer cells (Gjerdrum et al., 2010; Holland
et al., 2010; Sheridan, 2013; Paccez et al., 2014).
Interestingly, the induction of EMT TFs correlates with the
emergence of stem cell-like properties (Mani et al., 2008; Morel
et al., 2008). This suggests that the gain ofmesenchymal charac-
teristics might not only affect dissemination from primary tumors
but also boost the stem cell properties required for metastatic
outgrowth. However, epithelial characteristics are re-acquired
at metastatic locations via mesenchymal-to-epithelial transitions
(METs), typically leading to the establishment of secondary tu-
morswith epithelial phenotypes (Tsai et al., 2012). The outgrowth
of metastases requires cancer cell self-renewal and growth abil-
ity. Therefore, in the context of metastatic growth, ‘‘stemness’’ is
not strictly coupled to the mesenchymal features of cancer cells.
The potential advantage of a more mesenchymal state of cancer
cells at the metastatic site and the origin of their epithelial plas-
ticity remain unclear.
In this study, we use breast cancer models to demonstrate
that the EMT program is a key regulator of the enhanced niche
activation capacity of MICs at secondary sites. We identify
Thrombospondin 2 (THBS2) as amesenchymal state-dependent
effector of cancer cells that promotes stromal niche activation.
Subsequently, the newly activated stroma promotes cancer cells
to shift toward a more epithelial, BMP-dependent state compat-
ible with proliferation. We elucidated a biphasic temporal regula-
tion during metastatic colonization whereby the mesenchymal
status of cancer cells promotes stromal activation, which, in
turn, promotes cancer cell epithelial plasticity and their reversion
to a more epithelium-like phenotype.
RESULTS
MICs Display Partial EMT Features
In themouse breast cancerMMTV-PyMTmodel,MICswere iden-
tified by co-expression of the CD24 and CD90markers (Malanchi
et al., 2012). The gene expression profile of MICs (CD24+CD90+)
was compared to that of non-MICs (CD24+CD90) to generate a
MIC signature (Figure S1A). We verified that high levels of Wnt
signaling are a hallmark ofmetastatic cancer stem cells (Malanchi
et al., 2008, 2012; Nguyen et al., 2009; Reya and Clevers, 2005;
Vermeulen et al., 2010), along with other characteristics associ-
ated with their high metastatic potential, such as active trans-
forming growth factor b (TGF-b) signaling (Padua et al., 2008)
and Yap/Taz activity (Diepenbruck et al., 2014). We also found
that the MIC signature exhibited characteristic features of EMT
and its related extracellular matrix remodeling (Figure 1A and
S1B). In line with this, MICs freshly isolated from primary tumors
displayed a mesenchymal phenotype with higher expression of
Vimentin and the EMT-related receptor AXL as well as reduced
E-cadherin levels (Figures 1B and 1C). This more mesenchymal
phenotype was corroborated functionally using Matrigel collagen
matrices where MICs, either in pure or mixed non-MIC/MIC
spheroids, displayed enhanced single-cell invasive behavior
compared with non-MICs (Figures 1D, 1E, and S1C).
The capacity of MICs for invasion correlated with increased
expression levels of actin cytoskeleton regulators and extracel-Cell Replular matrix components (Figures S1D and S1E). EMT in MICs
was further confirmed by the higher expression and nuclear
localization of EMT TFs (Figures S1F and S1G). However, the
high level of heterogeneity within the MIC population suggests
a graded EMT with intermediate ‘‘partial EMT’’ states rather
than a simple binary transition. The MIC expression signature
also correlated with different secretome gene sets (Figure 1A).
Some of these secreted factors have been reported previously
to play a role in metastasis, such as TNC, SPARC, or CCL2 (Os-
karsson et al., 2011, Tichet et al., 2015; Qian et al., 2011).
We went on to investigate the influence that the observed par-
tial EMT status of MICs has on their capacity for metastatic initia-
tion following dissemination. Because the metastatic behavior of
MMTV-PyMT MICs might be regulated by the activity of other
pathways, such as WNT (Figure 1A), we selected a broader
mesenchymal cancer cell pool expressing AXL, including the
MIC (CD24+CD90+) population (Figure S2A). As expected, the
CD24+AXL+ population isolated from primary tumors displayed
partial mesenchymal features (Figures S2B and S2C). We next
tested CD24+AXL+ cells for their cancer initiation and metastatic
initiationpotential usingorthotopic transplantationand tail vein in-
jection, respectively (Figures 1F and 1G). Both assays require
cancer cell stemness to reinitiate and sustain a cancer cell
mass, either in a collective challenge within their organ of origin
with favorable niches or when seeded via circulation as single
cells in a likely less favorable ‘‘foreign’’ organ.Weobservednodif-
ference in primary tumor growth for CD24+AXL+ and CD24+AXL
cells, indicating that the subpools exhibit a comparable capacity
for cancer initiation (Figure 1H). Indeed, for MMTV-PyMT tumor
cells, more mesenchymal characteristics do not appear to influ-
ence tumor initiation ability. The more epithelial CD24+SCA1+
subpool (Figures S2D–S2F) identified previously for their tumor
initiation capacity (Liu et al., 2007) displayed a similar tumor
initiation potential as the more mesenchymal CD24+AXL+ or
MIC pools (Figures S2G–S2I). Strikingly, CD24+AXL+ cancer cells
show a higher lung metastasis competence compared with their
more epithelial counterparts (Figure 1I). This suggests that the
common mesenchymal characteristics observed within the
CD24+AXL+ and MIC CD24+CD90+ cancer cells might be linked
functionally to their metastatic competence, independent of an
advantage in intrinsic stemness potential displayed in a favorable
microenvironment.
MICs Promote Quicker Lung Fibroblast Activation
The highly secretory mesenchymal status of MICs might provide
an increased capacity of generating a favorable environment, or
niche, in distant sites (Figure 1A). We examined this suggestion
by analyzing the activation of lung stromata around disseminated
AXL+ or AXL cancer cell early after their extravasation into the
lungs. In linewithour hypothesis,CD24+AXL+cellsaresurrounded
by higher numbers of smoothmuscle actin (SMA)-activated fibro-
blastic stroma compared with CD24+AXL cells. We observed no
difference in their tissue localization, in particular in their proximity
to lung endothelial cells (Figures 2A–2D). To test whether niche
activation ability is a commonadvantage conferredby themesen-
chymal status of CD24+AXL+ and MIC pools, we measured the
ability of isolatedMICs to trigger features of cancer-associated fi-
broblasts (CAFs) in normal lungfibroblasts ex vivo. SortedMICsororts 13, 2456–2469, December 22, 2015 ª2015 The Authors 2457
Figure 1. The Mesenchymal Features of MICs Are Part of Their Metastasis-Initiating Potential
(A) Circos plot displaying selected gene signatures correlating positively with MIC-upregulated genes (see also Figures S1A and S1B). Black blocks highlight
metastasis-promoting genes either known (white) or described in this study (red).
(B and C) Representative immunofluorescence images (B) of non-MICs (CD24+CD90) and MICs (CD24+CD90+) stained with E-cadherin, Vimentin, and AXL
antibodies. Scale bar, 40 mm. Staining quantification is shown in (C). Data are from one representative experiment of five.
(D) Spheroid invasion assay. Shown are representative fluorescence images of MIC or non-MIC spheroids from actin-GFP/PyMT tumors in Matrigel:collagen I.
Scale bar, 100 mm.
(E) Mixed spheroid invasion assay. The histogram shows the number of cells invading as single cell (1:9 actin/GFP MICs:non-labeled non-MICs) in
Matrigel:collagen I (see also Figure S1C).
(legend continued on next page)
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non-MICs with a GFP-labeled normal lung fibroblast cell line
(NLF3) were plated and monitored for the induction of early fibro-
blast activation markers (Figure 2E). Because all cancer cells are
capable of fibroblast activation to some extent, we used low cell
numbers to increase the assay’s sensitivity. After 24 hr, fibroblasts
co-cultured with MICs exhibited early nuclear YAP translocation,
required forCAF induction, andhigher fibroblast activationprotein
(FAP) expression compared with fibroblasts cultured with non-
MICs (Figures 2F–2H; Calvo et al., 2013). To verify that the induc-
tion of these markers represents fibroblast activation, we per-
formed functional gel contraction assays to examine the ability
of fibroblasts to physically remodel the ECM. Limited numbers
of cell-sorted MICs or non-MICs from primary tumors were
seeded in the upper chamber of a trans-well dish. In the lower
chamber of the co-culture, normal lung fibroblasts (NFs) freshly
isolated from wild-type mouse lungs were embedded in
collagen-Matrigel matrices (Figure 2I). Importantly, we observed
that MICs trigger significantly greater fibroblast-driven gel
contraction comparedwith the other primary cancer cells (Figures
2J). In parallel, a gain of a CAF gene expression signature was
induced in fibroblast co-cultured with MICs. Collectively, these
data provide direct evidence that cancer cells displaying partial
EMT characteristics show an enhanced ability to generate acti-
vated fibroblasts, a crucial component of the metastatic niche.
Thrombospondin 2 Secretion Increases Stromal
Activation Capacity and Confers a Metastatic
Advantage in MICs
To understand the mechanism underlying the enhanced cap-
acity for fibroblast activation, we tested several MIC-specific
secreted proteins for their ability to activate fibroblasts (Figures
S3A and S3B).We found that purified recombinant THBS2 signif-
icantly enhanced the gel contraction capacity of fibroblasts (Fig-
ure 3A).We observed that exposure of lung fibroblasts to purified
THBS2 led to activation of integrin b1 and the phosphorylation of
its downstream effector focal adhesion kinase (pFAK) (Figures
3B and 3C). Importantly, a specific integrin b1-blocking antibody
(b1BA) arrested the THBS2-dependent integrin cascade as well
as fibroblast activation (Figures 3B–3D). To examine the role
THBS2 might play in tumorigenicity, we used a specific short
hairpin RNA (shRNA) targeting Thbs2mRNA (shTHBS2) to knock
down its expression in primary MMTV-PyMT cancer cells (PyMT)
(Figure 3E). Importantly, THBS2 depletion rendered cancer cells
less able to activate lung fibroblasts (Figure 3F). Furthermore,
shTHBS2 cancer cells were reduced dramatically in their capac-
ity for lung metastatic colonization upon intravenous injection
(Figure 3H). However, this is unlikely to be due to an effect on
intrinsic cancer cell stemness because shTHSB2 PyMT cells
maintained their ability to initiate early primary tumor growth
in vivo or form spheres in vitro (Figure 3G and S3C). Similar find-(F and G) Schematic showing a collective cell challenge for primary tumor growth
tail vein (G).
(H) Box plot showing the primary tumor burden in grams generated by the indicat
using the indicated cell numbers (n = 4/group). IV, intravenous.
(I) Box plot showing the lung metastatic burden 5 weeks after tail vein injection.
sentative images of lungs with GFP+ metastases.
Error bars represent SD in (C) and SEM in all other plots. *p < 0.05; ***p < 0.001;
Cell Repings were obtained using a second shRNA to block THBS2
secretion (Figures S3D–S3H). Because THBS2 is highly ex-
pressed in only a subset of PyMT cells, we tested the conse-
quence of exogenous Thbs2 gene expression in all PyMT cells.
Importantly, broad THBS2 secretion resulted in increased early
metastatic growth in the lungs upon direct seeding (Figure 3I).
These data support the clinical correlation of high Thbs2 expres-
sion with poor prognosis in advanced-stage human breast can-
cers (Figure S3I). Together, these results suggest that MICs
mediate efficient fibroblast activation through THBS2 secretion
and that this is critical for efficient metastatic initiation within
the secondary tissue.
The Niche Activation Capacity of Metastatic Cancer
Cells Depends on Their Partial Mesenchymal Status
The previous results reveal high niche activation ability as a
crucial characteristic of MICs. Interestingly, we also found that
their partial EMT phenotype defined by AXL expression was suf-
ficient to determine their metastatic competence (Figure 1I).
Therefore, we investigated whether the high niche activation
ability of MICs is linked functionally to their AXL mesenchymal
status. We used two approaches to downregulate AXL. First
we used the AXL-specific small molecule inhibitor R428 (Holland
et al., 2010), and second we used an shRNA to target AxlmRNA
(Gjerdrum et al., 2010). Brief exposure of MICs to R428 triggered
an overall shift toward a more epithelial phenotype with lower Vi-
mentin and AXL expression and higher E-cadherin levels (Fig-
ures 4A, 4B, and S4A). Accordingly, we detected a reduction in
the expression of EMT-TFs and motility in MICs (Figures S4B
and S4C). Similar phenotypic changes occurred in the basal hu-
man breast cancer cell line MDA-MB-231 (MDA231) following
treatment with R428. Indeed, although MDA231 cells, which ho-
mogeneously express AXL, typically display mesenchyme-like
features, a single pulse of R428 reduced the expression of AXL
and Vimentin and cell motility for up to 48 hr (Figures S4D–
S4G). Interestingly, upon R428-mediated mesenchymal inhibi-
tion, cancer cells also reduced the expression of secreted fac-
tors, including THBS2 (Figures 4C and S4H). Concomitantly,
the fibroblast activation ability of R428-treated metastatic cells
was impaired dramatically (Figure 4D). Because similar results
were found using an shRNA against Axl mRNA in primary
PyMT cells (Figure S5A), we can exclude non-specific effects
of the small molecule inhibitor R428. Indeed, shRNA-induced
AXL downregulation in PyMT cells reduced THBS2 secretion
and ex vivo fibroblast activation abilities (Figures 4E and 4F).
Notably, the expression of Thbs2 appears to be highly linked
to the expression of the Axl and Twist1 genes in human tumor bi-
opsies (Figure S4I). These data demonstrate that the mesen-
chymal status of MICs is directly related to their enhanced ca-
pacity for fibroblast activation.into mammary fat pads (F) or a single-cell challenge for lung metastasis via the
ed sorted cells after overnight culture. Shown are data from three experiments
Two independent experiments are shown (n = 5–6/group). Shown are repre-
****p < 0.0001; ns, not significant.
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Figure 2. MICs Have a Higher Capacity to Activate Fibroblasts
(A–D) Representative pictures showing single GFP+ cells (green) from the indicated subpools 72 hr after intravenous injection into RAG1-deficient mice. (A) DAPI
staining (blue) and SMA (red); quantified in (C). (B) DAPI staining (blue) and Endomucin (red); quantified in (D). Scale bars, 10 mm. n = 32–50 cells.
(E) Schematic of the cancer cell and GFP+ normal lung fibroblast cell line (NLF3) co-culture setting.
(F and G) Representative images of (F) early YAP nuclear translocation in NLF3 or (G) FAP levels in NLF3 cells 24 hr after plating. Scale bars, 40 mm (F), 70 mm (G).
(H) Chart indicating the levels of FAP in NLF3 cells from (G). Data are from one representative experiment of three.
(I) Schematic displaying the cancer cell and NLF3 co-culture setting.
(J) Representative images of the gel contraction by NLF3 assayed as in (I). The histogram shows the gel area of three independent experiments (n = 8/group).
(K) Quantitative real-time PCR analysis of the levels of CAF-defining genes in primary NF after co-culture with MICs (NF-MIC) or nonMICs (NF-nonMIC). Data are
from at least three experiments in triplicate normalized toGapdh. p = 0.0235 by ANOVA comparing differences between the NF, NF-non-MIC, and NF-MIC gene
signatures.
Error bars represent SD in (H) and SEM in all other plots. *p < 0.05, **p < 0.01, ****p < 0.0001. ns, non-significant.
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Figure 3. Cancer Cell-Derived THBS2 Enhances Fibroblast Activation
(A) Gel contraction induced by NLF3 after 3 days of exposure to recombinant CCL7 or THBS2. Top: representative NLF3-gels. Bottom: gel area quantification of
three independent experiments (n = 12/group).
(B and C) Levels of the active isoform of integrin b1 (clone 9EG7) and its downstream effector FAK (total or phosphorylated) in NLF3 for the indicated groups. Data
are from one representative experiment of two. Quantification is shown in (B) and representative images in (C). Scale bars, 20 mm.
(D) Gel contraction induced by NLF3 after co-culture with recombinant THBS2 with or without integrin b1-blocking antibody. Top: representative NLF3-gels.
Bottom: gel area quantification of two independent experiments (n = 4–16/group).
(E) Quantitative real-time PCR analysis of the mRNA expression level of Thbs2 by the indicated cells. Data are from three different experiments in triplicate
normalized to Gapdh.
(legend continued on next page)
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Cancer Cells Require AXL Mesenchymal Features to
Facilitate Fibroblast Activation
We showed that MICs isolated from primary tumors are in an
AXL-positive mesenchymal state. Therefore, we went on to
examine the mesenchymal status of cancer cells at the target
site by monitoring AXL expression during early colonization.
We detected two distinct phases of AXL expression: a first
phase, where the PyMT EMT MIC subpool maintains AXL, and
a second phase, where the AXL-positive phenotype is lost coin-
cidentally with MIC expansion in the lungs (Figure 5A). Similar
biphasic AXL expression was observed in the MDA231 cell line
(Figure 5B). Because the ability of cancer cells to trigger the
niche is crucial for metastatic establishment (Figure 3) and
dependent on the mesenchymal phenotype (Figure 4), we as-
sessed whether the maintenance of AXL is required for the first
phase of metastatic colonization. To do this, we inhibited AXL
activity only during the first colonization phase by pre-treating
cancer cells with the R428 inhibitor prior to intravenous injection
and continued treatment in vivo for 7 days (Figure 5C and S5B).
Notably, although R428 pre-treatment did not alter cancer cell
extravasation (Figure S5C), it did significantly reduce metastasis
after 5 weeks (Figures 5D–5F). Remarkably, only R428 pre-treat-
ment 24 hr before seeding into the lung was sufficient to inhibit
metastatic establishment (Figure 5E), suggesting that AXL
mesenchymal features are required early after metastatic cell
arrival to new tissue. Although short-term inhibition of AXL
decreased metastatic competence, this had no effect on prolif-
eration, self-renewal, and 3D cancer cell mass growth in vitro
(Figures S5D–5G), or primary tumor initiation in vivo (Figure S5H).
Interestingly, enhancing THBS2 expression in the MDA-MB-231
cell line partially rescued metastasis upon AXL inhibition in spite
of the fact that THBS2 overexpression only provided a positive
trend toward metastasis in these cells (Figures 5G, S5I, and
S5J). This result is in line with the observation that AXL-mesen-
chymal cells show a THBS2-mediated advantage in niche acti-
vation. We also observed a block in metastasis upon AXL inhibi-
tion using shRNA knockdown in PyMT cells (Figures 5H and 5I).
Furthermore, treatment of a second mouse breast cancer cell
line (4T1) with shTHBS2 or shAXL also reduced the metastatic
ability of 4T1 cells (Figures S5K and S5L). Together, these results
suggest that the first phase of metastatic colonization requires
the niche activation capacity provided by the AXL mesenchymal
characteristics.
Activated Stroma Modulates the EMT of Cancer Cells
toward a More Epithelial State
The previous results highlight the requirement of a mesenchymal
state for metastatic initiation upon seeding at the target site.
However, when cancer cells start growing within the metastatic
tissue, AXL expression is downregulated (Figures 5A, 5B, and(F) Gel contraction induced by NLF3 after co-culture with the indicated cancer c
dependent experiments (n = 10–12/group).
(G) Box plot showing early primary tumor growth of primary PyMT cells expressing
(H) Box plot showing the metastatic burden from PyMT cells expressing shCONT
The superficial lung metastasis number was evaluated.
(I) Box plot displaying the metastatic cell content by flow cytometry 20 days after t
Error bars represent SD in (B) and SEM in all other plots. *p < 0.05, **p < 0.01, **
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downregulation, GFP+ cancer cells growing in the lungs exhibit
reduced expression of the EMT transcription factor Twist1 (Fig-
ures 6B, 6C, S6A, and S6B). This suggests that the previously re-
ported EMT inhibition at the secondary site (Tsai et al., 2012) is
controlled temporally within the second phase of metastatic
colonization. Therefore, we investigated the changes that occur
in metastatic cells during this time period.
Ex vivo co-culture (as shown in Figure 2E) demonstrated that,
concomitant with fibroblast activation (Figures 2F–2H), MICs ex-
press lower levels of Axl, Twist1 (Figures 6D and 6E), and overall
EMT TF mRNA (Figure S6C). To track the phenotypic changes
during this time, cancer cells were co-cultured with CAFs for
24 hr under adherence conditions (Figure S6D). Here we found
that MICs reduced expression of Vimentin and AXL and
increased expression of E-cadherin (Figures S6E and S6F).
These results suggest that crosstalk between fibroblasts and
cancer cells triggers alterations in both compartments; namely,
activation of fibroblasts and consequent reacquisition of epithe-
lial characteristics by cancer cells. To functionally validate these
changes in the MIC EMT state, we analyzed their 3D invasion
modality as they first come in contact with CAFs. In line with pre-
vious studies (Gaggioli et al., 2007; Yu et al., 2014), carcinoma
cells in a non-invasive epithelial state (non-MICs) activated
both single and collective cell invasion modalities. Strikingly, in
line with the downregulation of mesenchymal markers, MICs dis-
played a notable reduction in single-cell migration when sur-
rounded by CAFs (Figures 6F and 6G).
We next investigated the potential molecular mechanism of
CAF-driven changes in cancer cells. TGF-b signaling has been
implicated extensively in metastasis (Padua et al., 2008). High
TGF-b signaling favors early metastatic colonization, whereas
its subsequent reduction is important for metastatic outgrowth
(Giampieri et al., 2009). Because TGF-b signaling, which is active
in MICs (Figure 1A and S1B), could be linked functionally to their
mesenchymal status (Diepenbruck et al., 2014), we assessed
whether modulation of TGF-b signaling in MICs associates with
the reacquisition of more epithelial characteristics. Using Image-
Stream analysis, we monitored the dynamics of activation of the
TGF-b effector SMAD2-3 in metastasizing cells in vivo. As AXL+
mesenchymal cells in the lung transit from the first to the second
phase of colonization, the number and staining intensity of
pSMAD2-3+ cells decreased similarly to Twist1 expression (Fig-
ure 6H, S6G, and S6I). These data are in agreement with the pre-
vious evidence showing that a reduction in TGF-b signaling is
required for the acquisition of the proliferative status necessary
for metastatic outgrowth (Massague´, 2008). Conversely, the
activation levels of BMP-dependent pSMAD1-5 was maintained
during the second phase of colonization, and the number of
pSMAD1-5+ cells increased (Figures 6I, S6H, and S6J). In lineells. Top: representative NLF3-gels. Bottom: gel area quantification of two in-
shCONTROL or shTHBS2 constructs in an orthotopic challenge (n = 6/group).
ROL or shTHBS2 constructs 5 weeks after tail vein injection (n = 7–11/group).
ail vein injection of PyMT control or THBS2ORF-expressing cells (n = 8/group).
*p < 0.001, ****p < 0.0001.
thors
Figure 4. TheMesenchymal Status of Cancer Cells Drives Fibroblast
Activation
(A) Representative images showing the expression of E-cadherin, Vimentin,
and AXL in MICs 24 hr after treatment with DMSO or R428. Scale bar, 20 mm.
See also Figure S4A.
(B) Axl gene expression levels in PyMT cells pre-treated with or without R428
as determined by quantitative real-time PCR analysis. Data are from three
different experiments in triplicate (normalized to Gapdh).
(C) THBS2 secretion in the media collected from the indicated cancer cells
24 hr after R428 pre-treatment as measured by ELISA. Left: PyMT subpools,
non-MIC data from three experiments in duplicate; MIC ± R428 treatment,
Cell Repwith this, we observed that the levels of inhibitor of differentiation
1 (ID1), a BMP/pSMAD1-5 target gene needed for cell prolifera-
tion during metastatic outgrowth (Gupta et al., 2007), were main-
tained, in particular in Twist1 cells (Figures 6J and 6K). Notably,
this modulation of ID1 in cancer cells could be recapitulated
in vitro by exposure to CAF-conditioned medium (CaCM), which
increases the levels of ID1 in a BMP-dependent manner (Figures
6L and 6M). Importantly, treatment with the specific inhibitor
LDN193189 in vivo resulted in reduced metastatic capacity (Fig-
ures 6N and 6O), suggesting that BMP/pSMAD1-5 activity does
indeed play a significant role in the second phase of colonization.
Together, these data show that, in the second colonization
phase, the phenotypic changes observed in metastasizing can-
cer cells toward a more epithelial state correlate with an inhibi-
tion of TGF-b signaling and the enhanced BMP signaling neces-
sary for metastatic outgrowth.
The Second Metastatic Colonization Phase Requires
Temporal Regulation for Efficient Metastatic
Establishment
We showed that the mesenchymal status of cancer cells during
the first phase of colonization is required for metastatic estab-
lishment. However, when CD24+AXL+ mesenchymal cancer
cells accumulate in the lung, they revert to an AXL-negative,
more epithelial state (Figure 5) following interaction with newly
activated fibroblasts (Figure 6). If these two events were linked
causally, then it would be expected that a temporal regulation
of epithelial plasticity is critical for metastatic outgrowth. Initially,
to probe this hypothesis, we induced an early mesenchymal
reversion of metastatic cells by R428 treatment during the sec-
ond phase of colonization (Figure 7A). This AXL inhibition no
longer blocks the metastatic establishment of MDA231 cells
(Figure S7A) and increases metastasis of primary PyMT cells
(Figures 7B and 7C), suggesting that inhibiting EMT in this phase
promotes metastasis. We observed that AXL inhibition in late-
stage metastases did not alter the number of metastatic nodules
(Figures 7A and 7B). Next, we delayed mesenchymal reversion
in vivo by exogenous expression of the Axl gene (LTR-AXL) in
cancer cells (Figure 7D). This leads to an exacerbated AXL-pos-
itive mesenchymal phenotype (Figures 7G, 7J, and S7B) without
altering the proliferation capacity (Figure S7C). Importantly, pre-
venting early AXL downregulation in metastasizing LTR-AXL-ex-
pressing cells delayed initial growth in the lungs (Figures 7E and
7F) and, ultimately, led to a reduction in the metastatic potential
of both PyMT and MDA231 cancer cells (Figures 7H, 7I, and 7K).
These data support the idea that downregulation of AXL isdata from seven experiments in duplicate. Right: MDA-MB-231 cell line
(MDA231), data from four experiments in duplicate.
(D) Gel contraction induced by NLF3 after exposure to MDA231 pre-treated
with DMSO or R428. Top: representative NLF3 gels. Bottom: gel area quan-
tification of three independent experiments (n = 12/group).
(E) THBS2 secretion in the media collected from the indicated cancer cells
24 hr after plating by ELISA. Data are from three different experiments in
duplicate.
(F) Gel contraction induced by NLF3 after exposure to the indicated cells. Top:
representative NLF3 gels. Bottom: gel area quantification of two independent
experiments (n = 7–9/group).
Error bars represent SEM. *p< 0.05, **p <0.01, ***p < 0.001. ns, non-significant.
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Figure 5. The Mesenchymal Status Is
Regulated Temporally during Metastatic
Colonization
(A) Flow cytometry analysis of the percentage of
AXL+ MICs (red, left y axis) and total MICs (black,
right y axis) among total GFP+ cancer cells in the
lung 4 and 12 days after tail vein injection (n = 8–9/
group from two independent experiments).
(B) Flow cytometry analysis of the percentage of
AXL+GFP+ MDA-MB-231 cells (MDA231) among
total GFP+ cancer cells in the lung 4 and 12 days
after tail vein injection (n = 3/group).
(C) Schematic of the R428 treatment setting for
PyMT or MDA231 cells. IV, intravenous.
(D) Box plot showing the metastatic burden of
MDA231 cells exposed to DMSO (n = 13) or R428
(n = 8) during the first week of colonization. The
superficial lung metastasis number was evaluated.
Shown are representative pictures of metastatic
lungs. Scale bar, 300 mm.
(E) Box plot displaying the metastatic burden of
PyMT cells pre-treated with DMSO (n = 14) or R428
(n = 5). In the last group (light blue, n = 9) mice were
additionally treated with R428 during the first week
of colonization. The superficial lung metastasis
number was evaluated.
(F) Representative H&E staining of metastatic lung
sections from the indicated mice. Scale bar,
100 mm.
(G) Box plot showing the metastatic burden of
control (Venus) or THBS2-expressing MDA231
cells treated as in (C) (n = 7–5/group). Micro-
metastases were evaluated in histological sections
of one lung lobe (see also Figure S5J).
(H) Box plot displaying early primary tumor growth
after orthotopic transplantation of the indicated
primary PyMT cells (n = 6/group).
(I) Box plot showing the metastatic burden of
the indicated PyMT cells after tail vein injection (n =
5–8/group). The superficial lungmetastasis number
was evaluated.
Error bars represent SEM. *p < 0.05, **p < 0.01,
****p < 0.0001. ns, non-significant.
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Figure 6. Attenuation of the Metastatic Cell Mesenchymal Phenotype
(A) Flow cytometry analysis changes in AXL expression in AXL+ cancer cells seeded in the lungs after the indicated times points (n = 8–9/group). Data are from one
representative experiment of two.
(legend continued on next page)
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required during the second colonization phase to allow the tran-
sition to a more epithelial proliferative state. Interestingly, the
overexpression of AXL in cancer cells led to a reduction in met-
astatic capacity specifically because an enhancement of primary
tumor growth was detected (Figure S7D). This is likely due to an
increase in AXL tyrosine kinase receptor activity at the early
stages of tumor initiation, leading to the generation of larger tu-
mors without obvious histologic changes after tumor establish-
ment (Figures S7E and S7F).
DISCUSSION
Successful establishment of metastases requires cancer cells
with self-renewal properties to disseminate from their tissue of
origin and re-initiate growth at secondary sites. The evidence
that experimental induction of EMT in epithelial cells triggers
stem cell characteristics suggests a unified mechanism for can-
cer metastasis. However, the plasticity of the EMT program from
dissemination to distant colonization during the metastatic pro-
cess makes the direct relationship between EMT and stemness
controversial (Tsai et al., 2012; Mani et al., 2008; Morel et al.,
2008; Wellner et al., 2009; Brabletz, 2012; Nieto, 2013) and sug-
gests that metastatic cancer cells are likely to undergo a partial
EMT that can be modulated toward a more mesenchymal or
epithelial state (Ombrato and Malanchi, 2014). Furthermore,
although the requirement of an EMT inhibition at the metastatic
site has been reported previously (Tsai et al., 2012), the dynamic
regulation of the mesenchymal/epithelial transition is currently
unknown. Using breast cancer models, we highlight the impor-
tance of the more mesenchymal phenotype of MICs during the
early phase of metastatic colonization. Moreover, we demon-
strate the requirement for AXL mesenchymal state-dependent
THBS2 secretion in mediating enhanced niche activation. We
also identify a subsequent phase of colonization where the
mesenchymal phenotype of cancer cells is downmodulated by
the interaction with the newly induced niche. This crosstalk leads
to inhibition of TGF-b signaling and pSMAD1-5-dependent
outgrowth, shifting cancer cells toward amore epithelial and pro-
liferative state. Blocking the effectors of these pathways during
this biphasic process reduces metastasis: THBS2 expression
during the first phase or pSMAD1-5 activity during the second
phase. Here we identify epithelial plasticity as a crucial determi-(B and C) ImageStream analysis changes in Twist1 expression in AXL+ cancer
Quantification of Twist1+ cells from one representative experiment of three. (C) C
(D and E) MIC changes after 3–5 days of co-culture with NLF3 as in Figure 2E. (
representative experiment (n = 4/group) of two. (E) ImageStream analysis of the p
group) of two.
(F and G) Spheroid invasion assay. Labeled MIC or non-MIC (green) spheroids we
Quantification of single (left) and collective (right) cell invasion. Data are from one
indicate single invading cells. Scale bar, 100 mm.
(H–K) ImageStream analysis of pSMAD2-3+ (H), pSMAD1-5+ (I), ID1+ (J), and ID1
group).
(L and M) Expression levels of ID1 in primary CD24+AXL+ tumor cells 24 hr after
determined by (L) western blot using Actin as a loading control (one representati
representative experiment of two).
(N) Schematic showing the in vivo LDN193189 treatment setting.
(O) Box plot displaying the metastatic burden of PyMT cells in mice treated with
(n = 9–12/group). Scale bar, 100 mm.
Error bars represent SD in (M) and SEM in all other plots. *p < 0.05, **p < 0.01, *
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AXL-dependent phenotypic modulation is sufficient to reduce
metastatic efficiency.
In agreement with the previously observed link between the
EMT program and the gain in stemness (Mani et al., 2008; Morel
et al., 2008), we found that the MICs of the MMTV-PyMT tumor
model (Malanchi et al., 2012) display a mesenchymal phenotype
(Figure 1A–1D and S1). However, using the EMT downstream
effector AXL as a marker for mesenchymal cancer cells, we
demonstrate that, within the MMTV-PyMT hierarchy, the mesen-
chymal features per se do not confer a differential tumor initiation
ability (Figure 1H and S2). Nonetheless, a more mesenchymal
state promotes growth at a less favorable distant environment
(Figure 1I). This correlates with a higher capacity of CD24+AXL+
cells to induce stromal activation early after infiltration of the sec-
ondary tissue (Figures 2A–2D). Our work suggests that the
increased intrinsic ability to trigger a favorablemicroenvironment
at the naive target site provides ametastatic initiation advantage.
Indeed, both the MIC subpool of MMTV-PyMT cancer cells as
well as the metastatic humanMDA-MB-231 cell line show higher
niche component activation ability according to their mesen-
chymal phenotype (Figures 2 and 4) and THBS2 secretion (Fig-
ure 3). We show here that THBS2 is capable of triggering fibro-
blast activation via integrin signaling and enhancing early
metastatic colonization (Figure 3I). This finding is supported by
computational analyses defining Thbs2 as one of the three genes
associated with a stromal desmoplastic reaction and high meta-
static risk (Kim et al., 2010) as well as by the clinical evidence of
its correlation with poor prognosis in high-grade human breast
cancers (Figure S3I). However, in rare circulating cancer cell
clusters that exhibit high metastatic potential, the mechanism
we describe may be circumvented (Aceto et al., 2014). In this
context, the cells within the cluster may create their own favor-
able niche and, therefore, bypass the requirement for a mesen-
chymal state and associated niche activation.
Our results support theconcept thatstemness isunperturbedby
themesenchymal/epithelial plasticityofmetastatic cells andcorre-
latewith a flexible partial EMT state rather thanwith a stable binary
EMT program.We confirmed that, to efficiently generate a cancer
cell mass at a distant site, cells regain amore epithelial phenotype
(Tsai et al., 2012). Notably, we now show that this modulation is
controlled temporally during the second phase of metastaticcells seeded in the lungs after the indicated times points (n = 4–5/group). (B)
ontour plot of representative lungs from (B) showing Twist1 staining intensity.
D) Flow cytometry quantification of AXL expression levels. Data are from one
ercentage of Twist1+ cells. Data are from one representative experiment (n = 4/
re imaged 48 hr after seeding into Matrigel:collagen I with or without CAFs. (F)
representative experiment of two. (G) Representative spheroid images. Arrows
+Twist1 (K) cell percentages in the lung 2 or 12 days post-seeding (n = 3–5/
exposure to the indicated media and in the presence of LDN193189 inhibitor
ve experiment of two) or (M) immunofluorescence staining quantification (one
vehicle or LDN193189. Shown are representative H&E-stained lung sections
**p<0.001, ****p < 0.0001. ns, non-significant.
thors
Figure 7. EMT-Stabilized Cells Do Not
Metastasize Efficiently
(A) Schematic showing the R428 treatment setting.
(B) Box plot displaying the metastatic burden of
mice injected with primary PyMT cells for the indi-
cated groups: DMSO, n = 11; R428, days 10–15,
n = 10; and R428, days 25–35, n = 7. The superficial
lung metastasis number was evaluated.
(C) Representative images of the indicated lung
sections. Scale bar, 100 mm.
(D) Schematic of the LTR-driven lentiviral plasmid
expressing the human Axl open reading frame
(ORF) (top) and control plasmid (bottom).
(E and F) Flow cytometry analysis showing the
percentage of total cancer cells (black) and AXL+
cells (blue) in the lung 3 or 4 days after intravenous
injection of MDA231 expressing the control-GFP
construct (E) or LTR-AXL construct (F). Data are
displayed as the group average relative to day 3
(n = 4–6/group).
(G) Representative flow cytometry plot showing the
expression levels of AXL in the indicated primary
PyMT cells.
(H) Box plot showing superficial lung metastasis
quantification after intravenous injection of PyMT
cells expressing control-GFP or LTR-AXL con-
structs (n = 10/group).
(I) Representative H&E staining of lung sections of
mice injected with MDA231 of the indicated
groups. Scale bar, 100 mm.
(J) Representative flow cytometry plot showing the
expression levels of AXL in the indicated MDA231
cells.
(K) Box plot showing the superficial metastasis
quantification after intravenous injection ofMDA231
cells expressing the control-GFP or LTR-AXL con-
structs (n = 8/group).
Error bars represent SEM. *p < 0.05, ****p < 0.0001.colonization (Figure 7). Indeed, prolonged Axl gene activation in
cancer cells strongly reduces metastatic ability (Figures 7H and
7K). AXL expression in the context of breast cancer lung metas-
tasis opposes primary tumor initiation (Figures 7G–7K and S7D),
likely because of differences in the requirement of its tyrosine ki-Cell Reports 13, 2456–2469, Denase receptor function, which is also
crucial for other cancer types (Ben-Batalla
et al., 2013).
Remarkably, we provide experimental
evidence that epithelial plasticity is medi-
ated by crosstalk between the cancer
cell and stroma (Figure 6). During the sec-
ond colonization phase, the newly acti-
vated fibroblasts generated during the
first phase induce a phenotype switch in
MICs. BMP-dependent ID1 activation in
cancer cells is triggered by exposure to
CaCM (Figures 6L and 6M). This effect,
observed in vitro, is corroborated in vivo
by theenhancement of pSMAD1-5activity
and downmodulation of TGF-b signaling
in favor of an ID1-positive proliferative
state. Indeed, treatment of mice with the specific BMP inhibitor
LDN193189 during the second colonization phase inhibits
metastasis (Figures 6N and 6O).
Overall, this study provides a refined definition of distant
colonization by more mesenchymal cancer cells where theircember 22, 2015 ª2015 The Authors 2467
niche-activation capacity is linked to their mesenchymal status
and THBS2 secretion. Subsequently, activated fibroblasts drive
MICs to revert to a more epithelial phenotype. This model high-
lights the importance of cancer cell-stroma crosstalk in modu-
lating the optimal phenotype for cancer cells during the dynamic
metastatic process.
EXPERIMENTAL PROCEDURES
Statistical Analysis
Statistical analyses were performed using Prism software (GraphPad Soft-
ware). p values were obtained from two-tailed Student’s t tests with paired
or unpaired adjustment. One-column t test was used for comparisons with a
normalized value. One-tailed t test was used for Figure 4E. Where indicated,
two-way ANOVA was used to perform multiple comparisons or multiple
variables analysis between experimental groups. Significance was set at
p < 0.05. Graphs show the symbols describing the p value (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001).
Animal Procedures
All experimental procedures involving mice were performed in accordance
with United Kingdom regulations under project license PPL 80/2531. Further
information can be found in the Supplemental Experimental Procedures.
ImageStream Analysis
Lungs or Matrigel collagen gels from co-culture experiments were digested
and dissociated to obtain a single-cell suspension, stained with a live/dead
fixable dye, fixed, and stained with the indicated primary antibodies (antibody
descriptions and working dilutions can be found in Table S4 and in the Supple-
mental Experimental Procedures). Tumor cells in the lung were identified by
GFP expression. The acquired ImageStream data were analyzed using Amnis
IDEA management software.
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Figure S1 (relates to Figure 1). MICs are in a highly secretory mesenchymal state  
(A) Heatmap represents the gene expression profile of MICs and nonMICs isolated from 
MMTV-PyMT primary tumors. The MIC signature includes all differently expressed 
genes in MICs compared to nonMICs (GEO:GSE63558). (B) Gene Set Enrichment 
Analysis (GSEA) plots show the correlation of the MIC signature with WNT and TGF-β 
target genes, and an EMT and YAP/TAZ signature (detailed information and references 
for each signature can be found in the Supplemental Experimental Procedures). (C) 
Images show a mixed spheroid stained with DAPI (blue) and F-actin (red). MICs from 
actin-GFP/PyMT tumors and nonMICs from non-labeled PyMT tumors were freshly 
isolated by cell sorting and re-aggregated overnight in suspension in a 1:9 MIC:nonMIC 
ratio mimicking the in vivo frequency of both populations. Note the invasive MIC cells 
identified by GFP (green) (quantification in Figure 1E). (D-F) Quantitative real time PCR 
analysis compares the gene expression levels of extracellular matrix components 
(D), actin cytoskeleton regulatory molecules (E) and EMT transcription factors (F) in 
MICs and nonMICs freshly isolated from three primary tumors. Data from 3 different 
experiments performed in triplicate (normalized to Gapdh). Bars represent mean ± 
sem. p<0.0001 by ANOVA comparing the MIC versus nonMIC gene sets in each 
plot. (G) Representative images show Zeb1 staining (green) and nuclear DAPI staining 
(blue) in sorted MICs and nonMICs. Cells were stained 24h after isolation and plating. 
Scale bar, 20 μm. Chart indicates the level of nuclear versus cytoplasmic intensity mean 
of Zeb1 (mean ± SD of the population). Data from one representative experiment out of 
2 are shown. 
 
 Figure S2 (relates to Figure 1). MICs are in a mesenchymal state defined by AXL 
expression  
(A) Venn diagram illustrates the relationship between the different PyMT populations and 
their relative frequency in PyMT tumors measured by FACS. MICs (CD24+CD90+) are 
represented in red, CD24+AXL+ in blue and CD24+SCA1+ in green. Mean ± sem for each 
population is indicated (n=5 tumors). (B) Representative pictures show E-Cadherin and 
Vimentin expression in MICs (CD24+CD90+) and CD24+AXL+. Cells were isolated by cell 
sorting from the same primary tumor and plated overnight on collagen-coated dishes 
prior to analysis. Scale bar, 15 μm. (C) Histograms indicate the percentage (mean ± 
sem) of E-Cadherin and Vimentin positive cells in MICs (CD24+CD90+) and CD24+AXL+ 
cells per field of view (representative pictures in B). Data from one representative 
experiment from a total of two are shown. (D) Representative pictures show E-Cadherin 
and Vimentin expression in the CD24+SCA1+ population of PyMT cells. Cells were 
isolated and analyzed as in (B). Scale bar, 15 μm. (E) Histogram indicates the 
percentage (mean ± sem) of E-Cadherin and Vimentin positive cells in the CD24+SCA1+ 
population per field of view (representative pictures in D). Data from one representative 
experiment of two are shown. (F) Plot displays together the percentage of E-Cadherin 
and Vimentin positive cells in the different PyMT populations evaluated in C and E. (G) 
Bar graph shows the weight (grams) of primary tumor formed by MICs, CD24+AXL+ and 
CD24+SCA1+ populations. Cells were sorted in the different pools from the same primary 
tumor cell preparation after overnight plating on collagen-I coated dishes. Either 103 cells 
or 104 cells from each population were orthotopically transplanted into mice and tumor 
growth was evaluated 30 and 20 days post-transplantation, respectively (n=4, number of 
tumors). (H) Table indicates the tumor initiation development over time of the indicated 
cell subpools after orthotopic transplantation (as in G). (I) Representative images of the 
tumors grown as specified in G, harvested 20 days post-transplantation of 104 cells. 
 
 Figure S3 (relates to Figure 3). THBS2 expression in MICs and Thbs2 knockdown 
characterization in primary PyMT cells  
(A) List of selected top secreted factors from the MIC signature in Figure S1A. Fold 
change expression of each factor obtained by comparing MIC versus nonMIC 
signatures. (B) Quantitative real time PCR analysis shows the expression levels of the 
secreted factors in MICs versus nonMICs. Data from 3 different tumors performed in 
triplicate (normalized to Gapdh). Bar represent mean ± sem. p=0.0057 by ANOVA 
comparing the gene set in MIC versus nonMIC. (C) (Left) Images show representative 
pictures of spheres formed by PyMT cells expressing shCONTROL and shTHBS2 I 
lentiviral constructs in suspension. Spheres were quantified 7 days after plating a single 
PyMT cell suspension (primary) and 7 days after passage (secondary). Scale bar, 200 
μm. (Right) Histogram shows the mean ± sem of the SFI (Sphere Formation Index) of 2 
independent experiments. (D) Histogram shows the relative levels of secreted THBS2 
measured by ELISA in media conditioned by PyMT cells expressing shCONTROL or 
shTHBS2 II lentiviral constructs. Data from 2 experiments performed in duplicate. Bars 
represent mean ± sem. (E) (Upper panel) Images show gel contraction by normal lung 
fibroblasts (NLF3) co-culture with or without primary PyMT cells expressing 
shCONTROL or shTHBS2 II lentiviral constructs. (Lower panel) Histogram shows the 
mean ± sem of the gel area in arbitrary units (n=4, number of gels per group). (F) Sphere 
formation assay by PyMT cells expressing shCONTROL and shTHBS2 II lentiviral 
constructs in suspension (as described in C). Histogram shows the mean ± sem of the 
SFI (Sphere Formation Index) of 3 independent experiments. (G) Early primary tumor 
growth of PyMT cells expressing shCONTROL or shTHBS2 II lentiviral constructs in a 
collective cell challenge. Middle line represents the mean, and horizontal lines the 
minimum and maximum value (n= mice per group: shCONTROL, 2; shTHBS2 II, 4). (H) 
Metastatic potential of total PyMT cells in the lung expressing shCONTROL or shTHBS2 
II lentiviral constructs 5 weeks after intravenous injection assessed by flow cytometry 
quantification of total GFP+ cells in the lung. Middle line represents the mean, and 
horizontal lines the minimum and maximum value (n=3 mice per group). (I) Kaplan-Meier 
plot shows the prognostic value of THBS2 in high-grade breast carcinoma represented 
as Distant Metastasis-Free Survival (DMFS) of grade 3 breast cancer patients classified 
according to Thbs2 expression levels. Data from Gene expression-based Outcome for 
Breast cancer Online (GOBO) database. 
 
 
Figure S4 (relates to Figure 4). Effects of R428 AXL inhibitor on cancer cells 
mesenchymal state  
(A) Charts show the quantification of the expression levels of E-Cadherin, Vimentin and 
AXL in sorted MICs cultured overnight in collagen-I coated dishes and treated 24h 
before analysis with DMSO or 1.5 μM R428 for 3h. Data from one representative of 
three experiments are shown. Error bars indicate mean ± SD of the population (see 
Figure 4A for representative pictures). (B) Quantitative real time PCR analysis compares 
the gene expression levels of different EMT transcription factors in MICs 24h after 
treatment with DMSO or 1.5 μM R428 for 3h. Data from 3 different experiments 
performed in triplicate (normalized to Gapdh). Error bars represent mean ± sem. 
p=0.0308 by ANOVA comparing the gene set in MICs versus MICs-R428. (C) Rose 
plots show the tracking path of MICs 24h after treatment with DMSO or 1.5 μM R428 
for 3h. Histogram shows the mean ± sem of the cell speed quantified in 2 
independent experiments. (D) Flow cytometry histograms show the expression levels 
of AXL in the MDA231 cell line 24h, 48h or 72h after treatment with 3 μM R428. (E) 
Flow cytometry analysis of the percentage of AXL+ cells in the MDA231 cell line 24h, 
48h or 72h after treatment with 3 μM R428. (F) Representative immunofluorescence 
images show the expression levels of Vimentin and AXL in MDA231 cells 24h after 
treatment with DMSO or 3 μM R428 for 3h. Charts indicate the quantification of 
expression levels of Vimentin (left) and AXL (right) in the above-indicated conditions. 
Data from one representative experiment from of two are shown. Line and error bar 
indicate mean ± SD of the population. (G) Rose plots show the tracking path of 
MDA231 cells 24h after treatment with DMSO or 3 μM R428 for 3h. Histogram 
shows the mean ± sem of the cell speed quantified in 2 independent experiments. 
(H) Quantitative real time PCR analysis compares the gene expression levels of 
selected secreted factors in nonMICs and MICs isolated from primary tumors and 
treated 24h before analysis with DMSO or 1.5 μM R428 for 3h. Data from 3 different 
experiments performed in triplicate (normalized to Gapdh). Bar represent mean ± sem. 
p=0.0041 by ANOVA comparing the gene set in MICs versus MICs-R428. (I) Plots show 
the correlation between Thbs2 gene expression and Axl, or Twist1 expression in human 
invasive breast carcinoma biopsy samples. Data sets and analysis can be found at 
cBioPortal for Cancer Genomics (www.cbioportal.org). Further details are provided in the 
Supplemental Experimental Procedures. 
 
 
 Figure S5 (relates to Figure 5). Effects of THBS2 and AXL altered levels in tumor 
cell behavior 
(A) Flow cytometry dot plot overlaid shows AXL expression in primary PyMT cells 
expressing shCONTROL (black dots) and shAXL (blue dots) lentiviral constructs. (B) 
Flow cytometry analysis of AXL+ cancer cells in the lung after R428 treatment in vivo. 
Mice were intravenously injected with primary PyMT GFP+ cells and treated daily with 
DMSO (vehicle) or R428 (12.5 mg/kg) for 3 days, when lungs were extracted for 
analysis. Chart shows mean ± sem (n=3-5 per group). (C) Flow cytometry analysis to 
assess MICs and nonMICs cell extravasation into the lung after R428 pre-treatment in 
vitro. PyMT/GFP+ cells were treated 24 hours prior to intravenous injection into mice with 
DMSO or 1.5 μM R428 in vitro. Flow cytometry analysis was performed 24h post-
injection after lung perfusion. Chart displays the mean ± sem (n=5-6 per group). (D) Flow 
cytometry analysis shows BrdU incorporation over a 3 hours pulse by primary PyMT 
cells 24h after treatment with DMSO or 1.5 μM R428 for 3h. Data collected from 3 
different tumors preparations performed in duplicate. (E) Flow cytometry analysis shows 
BrdU incorporation over a 3 hours pulse by MDA231 cells 24h after treatment with 
DMSO or 3 μM R428 for 3h. Histogram shows mean ± sem of 2-3 MDA231 cancer cell 
line preparations. (F) Sphere culture assay. (Left) Images show representative pictures 
of spheres formed by primary PyMT cells 7 days after pre-treatment with DMSO or 1.5 
μM R428. Scale bar, 200 μm. (Right) Histogram shows mean ± sem of 3 independent 
experiments. Spheres were quantified 7 days after plating a single PyMT suspension 
(primary) and 7 days after passage (secondary). (G) Organoid assay. Images show 
representative pictures of organoids formed by primary PyMT cells embedded in 
Matrigel 7 days after pre-treatment with DMSO or 1.5 μM R428. Scale bar, 200 μm. 
Histogram shows the mean ± sem of the wells (n=3-4) assessed in 2 independent 
experiments. (H) Box plot displays tumor burden evaluated 3 weeks after engraftment of 
PyMT cells (left) or MDA231 cells (right) pre-treated with DMSO or 1.5 μM R428 (PyMT) 
or 3 μM R428 (MDA231) (n=6, mice per group). (I) Quantitative real time PCR analysis 
shows Thbs2 gene expression levels in MDA231 cells expressing Venus (control) or 
THBS2ORF lentiviral constructs (normalised to Gapdh). Data show technical duplicates.  
(J) Box plot shows the metastatic burden after intravenous injection of MDA231 cells 
expressing VENUS or THBS2ORF lentiviral constructs (n=5-7 mice per group). 
Micrometastasis were evaluated in lung histological sections (rest of the experiment is 
displayed in Figure 5G). (K) Box plot shows the metastatic burden after intravenous 
injection of 4T1 cell line expressing shCONTROL, shAXL or shTHBS2 lentiviral 
constructs (n=4, mice per group). Number of superficial lung metastasis was evaluated. 
(L) Representative images of lung sections stained with Hematoxylin and Eosin from (K). 
Scale bar, 100 μm. 
 
 Figure S6 (relates to Figure 6). In vivo and in vitro mesenchymal cancer cells 
phenotypic modulations  
(A) Bar graph shows the intensity mean of Twist1 in CD24+AXL+ cells in the lung in a 
metastasis time course analyzed by ImageStream. Data from three independent 
experiments are shown (n=3-5, mice per group). P value determined comparing the 
differences in Twist1 intensity at day 2 and day 12 of metastasis across the three 
experiments by ANOVA. (B) Representative ImageStream images show GFP+ cells 
(green) isolated from metastatic lungs injected with CD24+AXL+ tumor cells 2 or 12 days 
prior to analysis stained for nuclear DAPI (blue) and Twist1 (red); intensity quantification 
in A. (C) Quantitative real time PCR analysis compares the gene expression levels of 
different EMT transcription factors in MICs co-cultured with or without NLF3 as in Figure 
2E. Data from 2-3 different experiments performed in triplicate (normalized to Gapdh). 
Error bars represent mean ± sem. p=0.0018 by ANOVA comparing the gene set in MICs 
versus MICs-NLF3. (D) Schematic shows the co-culture setting where MICs are seeded 
in adherent condition on collagen-I coated dishes in the lower compartment and CAFs in 
the upper chamber for 24h. (E) Representative images show the expression of E-
Cadherin, Vimentin and AXL in MICs co-cultured with or without CAFs for 24 hours as in 
D. Scale bar, 20 μm. (F) Charts indicate the expression levels of E-Cadherin, AXL and 
Vimentin in MICs co-cultured with or without CAFs for 24 hours. Data from one 
representative experiment of two are shown. Line and error bar indicate mean ± SD of 
the population. (G-H) Flow cytometry contour plots generated by ImageStream show the 
overall intensity of Twist1 versus pSMAD1-5 (G) or pSMAD2-3 (H) in CD24+AXL+ tumor 
cells in the lung 2 days (blue) and 12 days (red) post intravenous injection. Note the 
overall decrease in Twist1 and pSMAD2-3 staining intensity while pSMAD1-5 is 
maintained. (I-J) Representative ImageStream images show GFP+ cells (green) isolated 
from metastatic lungs injected with CD24+AXL+ tumor cells 12 days prior to analysis 
stained for nuclear DAPI (blue) and pSMAD2-3 (yellow) and Twist1 (red) (I) or pSMAD1-
5 (yellow) and Twist1 (red) (J).  
 
 Figure S7 (relates to Figure 7). AXL exogenous expression in tumor cells 
(A) Box plot displays the metastatic burden of MDA-MB-231 (MDA-231) cells 
intravenously injected into mice that were treated in vivo with DMSO or 12.5 mg/kg of 
R428 from day 10-15 post-injection (as described in Figure 7A). n= number of mice, 
CONTROL, 3; R428 (Day 10-15), 4. (B) Charts indicate the expression levels of 
Vimentin (left) and AXL (right) in MDA231 cells expressing GFP control or LTR-AXL 
constructs. Data from one representative experiment from two are shown. Line and error 
bar indicate mean ± SD of the population. (C) BrdU incorporation over a 3 hours pulse 
by MDA231 cells expressing GFP control or LTR-AXL constructs. Histogram indicates 
mean ± sem of four independent experiments. (D) Box plots display the tumor burden 
assessed 2 weeks after engraftment of PyMT (upper panel) or MDA231 (lower panel) 
cells expressing GFP or LTR-AXL constructs (n=6 tumors per group). (E-F) Histological 
images of representative PyMT (E) or MDA231 (F) primary tumors expressing GFP or 
LTR-AXL constructs stained with Hematoxylin and Eosin, Ki67 or Endomucin. Scale 
bars, 100 μm. 
 
  
• Supplemental Tables 
Table S1. Mouse RT-PCR primers: relates to Figure S1D-F, S3B, S4H, S5I and S6C 
GENE SYMBOL Forward (5’ – 3’) Reverse (3’ – 5’) 
Gapdh CGTGTTCCTACCCCCAATGT TGTCATCATACTTGGCAGGTTTCT 
Snai1 CTCTGAAGATGCACATCCGAA GGCTTCTCACCAGTGTGGGT 
Snai2 TGTGTCTGCAAGATCTGTGGC TCCCCAGTGTGAGTTCTAATGTG 
Twist1 
GCCGGAGACCTAGATGTCATTG CACGCCCTGATTCTTGTGAA 
Zeb1 GCCAGCAGTCATGATGAAAA TATCACAATACGGGCAGGTG 
Myl9 AGGCCTCAGGCTTCATCCACGA ATGGGGTCTAGGCACTGGGGC 
Amotl2 AACCGCCACCTGGCAAGCAA GGTCCTCGATGGCACCACGC 
Ankrd1 AAACGGACGGCACTCCACCG CGCTGTGCTGAGAAGCTTGTCTCT 
Ccl2 CAGGTCCCTGTCATGCTTCT GTCAGCACAGACCTCTCTCT 
Ctgf GCTTCGCAGGGCCTGACCAT GCCGTGGGCTGCATTCCTCT 
Icam1 GAAGCTTCTTTTGCTCTGCC AGCAGTACTGGCACCAGAAT 
Plac8 TCAGTGACTGCGGAGTCTGCC CAGAGCTCTTGCCATCCAGCTCC 
Spdr GCCCAGCAGGTGCGCTATGA CGGGGTGGCTTCCACGAGGT 
Tagnl AGGCGGCCTTTAAACCCCTCACC CGGCCTACATCAGGGCCACAC 
Thbs1 GCGTTGCCAGGCTCCGAGTT GGTGCGCAGGCCCTTCAGTT 
Angtl4 AAGATGCACAGCATCACAGG ATGGATGGGAAATTGGAGC 
Ccl7 AGCTACAGAAGGATCACCAG CACATTCCTACAGACAGCTC 
Ccl11 CAGATGCACCCTGAAAGCCATA TGCTTTGTGGCATCCTGGAC 
Cxcl10 GACGGTCCGCTGCAACTG GCTTCCCTATGGCCCTCATT 
Cyr61 GCCGTGGGCTGCATTCCTCT GCGGTTCGGTGCCAAAGACAGG 
Wnt5A GGTGCCATGTCTTCCAAGTT ATCACCATGCCAAAGACAGA 
Col1A1a TCGTGGCTTCTCTGGTCTC CCGTTGAGTCCGTCTTTGC 
Col4A1 a ATAGCCAAAGCCAAACCCATT CGCAGAGCAGAAGCAAGAA 
Lama2 a GTATCACCAAATTATCCAAGACCAT TCGCTGGGCATATTTCTCATC 
Fn1 a AAGAGGACGTTGCAGAGCTA AGACACTGGAGACACTGACTAA 
Mmp2 a GGACAAGAACCAGATCACATACA GCCCGAGCAAAAGCATCAT 
Mmp9 a TGATGCTATTGCTGAGATCCAG CCTGTAATGGGCTTCCTCTATG 
Mmp13 a CCAACCCTAAGCATCCCAAA TCCTCGGAGACTGGTAATGG 
Mmp14 a CCATCAATACTGCCTACGAGAG CTCCTTAATGTGCTTGGGGTAC 
Fscn1 a AAAGACTCCACGGGCAAGTA GTCACAGAACTCAAGGAAGAAATC 
LimkI a TCTACAAGGACAAGCGGCTAA CTCTGACTCCACGGGTACTG 
Myhl10 a TCAGATGACGACACAGAAAGTAA AGACTGGTGCTGGGATGAG 
Pfn1 a ACCGTTCCCTTTGGCTTTTG ATGTGGTTTTGGCAGCAATAAG 
Mylk a CCACCAGCACCATCACTCT CCCAGGAGAGAAGGACCCTA 
Thbs2 a GCCACCAGAACAACCAAGAC CACCATCATTGTCATCATCAGAGT 
Acta2 a CTCTTCCAGCCATCTTTCATTG GTTGTTAGCATAGAGATCCTTCCT 
 
a Design and validated by PrimerDesign Ltd, UK. 
 
 
Table S2. Lentiviral plasmids description: relates to Supplemental Materials and 
Methods, 7.1. Lentiviral constructs generation 
Name Promoter /downstream sequence Marker  Notes 
GFP LTR hPGK-EGFP Mild expression 
LTRAXL LTR-hAXLORF hPGK-EGFP Mild expression 
shCONTROL H1 hPGK-EGFP High expression 
shAXL H1-mshAXL hPGK-EGFP High expression 
shTHBS2 I H1-mshTHBS2 I hPGK-EGFP High expression 
shTHBS2 II H1-mshTHBS2 II hPGK-EGFP High expression 
VENUS mPGK hPGK-VENUS High expression 
THBS2ORF mPGK-mTHBS2ORF hPGK-VENUS High expression 
 
 
Table S3. shRNA sequences: relates to Supplemental Materials and Methods 7.1. 
Lentiviral constructs generation 
shRNA TARGET SEQUENCE (5’ – 3’) 
shAXL F GACATCTTCTTTCTCATGTGAAGCCCATCTGGTCATGGGCTTCACATGAGAAAGAAGATGTC
TTTTT 
shAXL R AAAAAGACATCTTCTTTCTCATGTGAAGCCCATGACCAGATGGGCTTCACATGAGAAAGAAG
ATGTC 
shTHBS2 F GCTGTAGGTTTCGACGAGTTTCTCGAGAAACTCGTCGAAACCTACAGCTTTTT 
shTHBS2 R AAAAAGCTGTAGGTTTCGACGAGTTTCTCGAGAAACTCGTCGAAACCTACAGC 
shTHBS2 II F CCACGTCAAGGACACTTCATTCTCGAGAATGAAGTGTCCTTGACGTGGTTTTT 
shTHBS2 II R AAAAACCACGTCAAGGACACTTCATTCTCGAGAATGAAGTGTCCTTGACGTGG 
 
 
Table S4. Antibodies list: relates to Supplemental Materials and Methods 6.1. 
Histology; 10. Western blot; 11. BrdU assay; 13. Flow Cytometry and 14. 
Immunofluorescence 
ANTIBODY COMPANY CATALOG
UE No 
CLONAL (CLONE) DILUTION 
(TECHNIQUE) 
Endomucin Santa Cruz sc-65495 Rat monoclonal (V.7C7) 1:200 (IHC-P) 
Ki67 (human) Dako A047 Rabbit polyclonal 1:500 (IHC-P) 
Ki67 Novocastra  NCL-Ki67p Rabbit polyclonal 1:200 (IHC-P) 
FAP-α Santa Cruz sc-54539 Goat polyclonal 1:100 (IF) 
YAP Santa Cruz sc-101199 Mouse monoclonal (63.7) 1:50 (IF) 
Vimentin (human) Abcam ab8978 Mouse monoclonal  1:100 (IF) 
Vimentin Sigma V2258 Mouse monoclonal (LN-6) 1:200 (IF) 
E-Cadherin Abcam ab11512 Rat monoclonal (DECMA-1) 1:200 (IF) 
Twist1 Santa Cruz sc-81417 Mouse monoclonal 1:50 (FC) 
Zeb1 Santa Cruz Sc-25388 Rabbit polyclonal 1:100 (IF) 
AXL-biotinylated R&D systems BAF854 Goat polyclonal 1:100 (FC) 
AXL R&D systems MAB8541 Rat polyclonal 1:100 (IF) 
AXL (human) R&D systems MAB154 Mouse polyclonal 1:100 (IF/FC) 
Integrin-β1 active BD bioscience 550531 Rat monoclonal (9EG7) 1:50 (IF) 
Integrin-β1 Abcam ab24693 Mouse monoclonal (P5D2) 1:100 (B/IF) 
CD24-AF450 eBioscience 48-0242-
82 
Rat monoclonal (M1/69) 1:100 (FC) 
CD90-APC eBioscience 17-0900-
82 
Mouse monoclonal (HIS51) 1:100 (FC) 
SCA1-FITC eBioscience 11-5981-
82 
Mouse monoclonal (D7) 1:100 (FC) 
CD31-PE eBioscience 12-0311-
82 
Rat monoclonal (390) 1:300 (FC) 
CD45-PE eBioscience 12-0451-
82 
Rat monoclonal (30-F11) 1:300 (FC) 
Ter119-PE eBioscience 12-5921-
82 
Rat monoclonal (Ter-120) 1:300 (FC) 
FAK Santa Cruz sc-558 Rabbit polyclonal 1:300 (IF) 
pFAK Santa Cruz sc-16563-
R 
Rabbit polyclonal 1:50 (IF) 
ID1 Biocheck BCH-
1/195-14 
Rabbit monoclonal (195-14) 1:100 (IF) / 
1:5000 (WB)  
pSMAD1-5 Cell signal 9511 Rabbit monoclonal (D5B10) 1:20 (FC) 
pSMAD2-3 Cell signal 8828 Rabbit monoclonal (D27F4) 1:20 (FC) 
BrdU Abcam ab6326 Rat monoclonal (BU1/75 
ICR1) 
1:100 (FC) 
SMA-cy3 Sigma C6198 Mouse monoclonal (1A4) 1:300 (IF) 
 
• All antibodies are mouse specific, unless otherwise specified. 
• IF: Immunofluorescence 
• FC: Flow cytometry 
• WB: Western Blot 
• IHC-P: Immunohistochemistry – paraffin embedded tissue 
  
• Supplemental Experimental Procedures 
1. Statistical Analysis 
Statistical analyses were performed using Prism software (GraphPad Software). P 
values were obtained from two-tailed Student t-tests with paired or unpaired 
adjustment. One column t-test was used for comparisons to a normalized value. One 
tail t-test was used for Figure 4E. Where indicated two-way ANOVA was used to 
perform multiple comparisons or multiple variables analysis between experimental 
groups. Significance was set at p<0.05. Graphs show the symbols describing p value 
(*, p<0.05; **, p<0.01; ***, p<0.001; ****, p< 0.0001). 
 
2. Microarray samples and data analysis 
.2.1 Accession Numbers 
Microarray expression data were deposited in the Gene Expression Omnibus (GEO) 
database, available at http://www.ncbi.nlm.nih.gov/geo/. The accession number for the 
array data reported in this paper is GEO:GSE63558.  
 
.2.2 Array samples preparation 
MICs and nonMICs were freshly FACS sorted from late stage PyMT tumors according to 
their CD24-CD90 expression. RNA isolation was performed using MagMax-96 Total 
RNA Isolation Kit (AM1830, Ambion) that allows high quality RNA extraction from 
samples with low cell numbers, <10,000 cells. RNA quality for each sample was 
assessed using Agilent RNA 6000 Pico Kit (5067-1511, Aligent Technologies) and only 
those samples with a RNA Integrity Number (RIN)>9 were considered for processing. 
RNA was amplified and analyzed on Illumina gene expression arrays (mouse) at the 
Barts and London Genome Centre. 
 
.2.3 Gene expression data analysis 
Gene expression data were analyzed by the Bioinformatics Unit at The Francis Crick 
Institute using Bioconductor version 2.2 available at http://bioconductor.org, running on 
R version 2.7.1 (R Core Team, 2013) available at http://www.R-project.org/. Normalized 
probe set expression values were calculated using log2 transformation and quantile 
normalization using the 'lumi' package (Du et al., 2008). To determine significant 
differences of expression levels between the different groups, a moderated Student's t 
test was computed on a probe-by-probe basis using the empirical Bayes statistics in the 
'Limma' package (Smyth, 2005). The resultant p-values were adjusted for multiple 
testing using the False Discovery Rate (FDR) Benjamini and Hochberg method 
(Benjamini et al., 1995), where any probe sets that exhibited an adjusted p-value FDR 
q<0.05 were called differentially expressed. 
 
Differentially expressed genes identified from MICs versus non-MICs (MIC signature) 
were used to generate a hierarchical Heatmap (Figure S1A). Genes were clustered 
using a Euclidean distance matrix and average linkage clustering. Red indicates higher 
expression and blue indicates lower expression relative to the mean expression of 
probes across the four samples. 
  
Differentially expressed genes were used to determine enrichment of pathways and 
processes using MetaCoreTM integrated software, version 6.19 developed by Thomson 
Reuters (2014), available at http://thomsonreuters.com/metacore/. This analysis employs 
a hypergeometric distribution to determine whether a list of differentially expressed 
genes is enriched in a pathway or process gene set relative to all genes on the array. 
Pathways or processes that showed a FDR of less than 0.05 were called enriched. The 
circos plot was generated plotting the top overexpressed pathways in MICs and a 
selection of their associated genes with reported roles in metastasis (Figure 1A).  
 
.2.4 GSEA  
The MIC signature was analyzed using the GSEA software developed by the Broad 
Institute of MIT and Harvard (USA) and available at www.broadinstitute.org, following the 
program guidelines to determine the correlation of specific published signatures with the 
MIC signature. The specific settings applied in all analyses are: number of permutations 
- 1,000, permutation type - gene set, enrichment statistic -weighted, metric for ranking 
genes - t-test. The rest of the fields were left as defaulted. The Wnt target genes 
signature was downloaded from the Wnt homepage Stanford University, available at 
http://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes. The signature 
comprises a list of validated Wnt/β-catenin target genes. Farmer et al. previously 
published the TGF-β target genes and EMT signature (Farmer et al., 2009). Last, 
Dupont et al. published the YAP/TAZ signature (Dupont et al., 2011). 
 
3. In silico data analysis 
.3.1  cBioPortal for Cancer Genomics 
The correlation analysis between the gene expression levels of Thbs2 and different EMT 
markers was performed using cBioPortal for Cancer Genomics develop by Memorial 
Sloan Kettering Cancer Center (Cerami et al., 2012; Gao et al., 2013) and available at 
http://www.cbioportal.org/public-portal/. The tumor data set used was The Cancer 
Genome Atlas (TCGA provisional), Breast Invasive Carcinoma project (Cancer Genome 
Atlas, 2012). 
 
.3.2 GOBO 
Distant Metastasis-Free Survival (DMFS) prognosis prediction according to Thbs2 gene 
expression levels and tumor grade in breast cancer patient data was done using GOBO 
(Gene expression-based Outcome for Breast cancer Online) 1.0.1 database developed 
by the Department of Oncology of Lund University and Skåne University Hospital (Lund, 
Sweden) and available at http://co.bmc.lu.se/gobo/. The tumor data set consists of 1881 
samples (Ringner et al., 2011). All tumor types were selected for the analysis, splitting 
data in 3 quantiles and selecting 5 years for censoring data. 
 
4. Quantitative real time PCR 
For quantitative RT-PCR, RNA preparation was performed using either MagMax-96 
Total RNA Isolation Kit (AM1830, Ambion) when RNA was isolated from less than 105 
cells per sample, or RNeasy Mini Kit (QIAGEN) for higher cell numbers per sample. 
cDNA synthesis was performed using and SuperScript III First-Strand Synthesis System 
(Invitrogen), according to the manufacturer’s protocol.  
Quantitative real-time PCR samples were prepared with 25ng total cDNA for each PCR 
reaction. The PCR, data collection and data analysis were performed on a 7500 FAST 
Real-Time PCR System (Life Technologies). The mouse primer pairs used for each of 
the mRNA targets are shown in Table S1.  
 
5. Animal procedures 
.5.1 Mouse strains 
Transgenic FVB/n mice expressing the Polyoma Middle T-antigen (PyMT) oncogene 
under the Mouse Mammary Tumor Virus promoter (MMTV-PyMT) (Guy et al., 1992) 
were obtained from Dr Erik Sahai and used as sources of primary cancer cells. Cells 
were always isolated from late stage carcinomas. 
RAG1 deficient FVB/n mice were obtained from Dr Joerg Huelsken. Age matched 6 to 
10 weeks female were used as recipients for all orthotopic tumor transplantations and 
tail vein injections experiments, unless otherwise specified. 
Nude (NuNu) CD1 mice were bought from Harlan UK and used for obtaining the 
samples for the microarray analysis. All the mice were kept in accordance with UK 
regulations under project license PPL 80/2531. 
 
.5.2 Tumor initiation and metastatic colonisation assays 
In tumor initiation assays (collective challenge), unless otherwise specified either 3x105 
PyMT primary cells or 1x106 MDA-MB-231 cells were mixed in 100 μl of Growth Factor 
Reduced Matrigel (356230, Corning), and injected into the mammary fat pad of 
anesthetized mice. Tumor growth was evaluated 20 days after injection for early tumor 
initiation, and 6 weeks post-transplantation to evaluate differences in primary tumor 
growth and microenvironment. 
 
For experimental metastasis assays (single cell challenge), unless otherwise stated, 
between 5x105 – 1x106 PyMT primary cells or 1x106 MDA-MB-231 cells were 
resuspended in 100μl PBS and injected into the tail vein of mice. For metastatic assays 
where unlabeled PyMT and MDA-MB-231 cells were used, macrometastasis were 
evaluated either quantifying the number of superficial metastatic nodules using a Zeiss 
Lumar V.12 stereomicroscope or by histological analysis after Hematoxylin and Eosin 
(H&E) stain of lung sections. Other metastatic assays were performed using 
endogenously expressing, or lentivirus induced, GFP+ or Venus+ cells. Here metastasis 
were evaluated by quantifying the number of fluorescent metastatic nodules using Lumar 
V.12, (Zeiss), or by evaluating the percentage of GFP+ cancer cells in the lung by FACS 
analysis. 
 
.5.3 Drug treatments 
R428, also known as BGB324 (1946, Axon MedChem), was dissolved in DMSO at a 
final concentration of 21.15 mM or 12.5 mg/ml. In vivo treatments were performed as 
previously described (Holland et al., 2010). Briefly, for the 24 hours treatment time point, 
PyMT cells were treated in vitro with either vehicle (DMSO) or 1.5 μM R428 for 3 hours, 
24 hours before injection. The MDA-MB-231 cell line was pre-treated in vitro with 3 μM 
R428 for 3 hours, 24 hours before experiments were performed. For treatment during 
the first week of metastasis, cells were pre-treated in culture as described above, and 
after tail vein injection mice received a daily dose of 12.5 mg/kg R428 by oral 
administration. Treatments between 10-15, and 25-35 days post-injection were 
performed as described above, but cells were not pre-treated in culture before injecting 
them. 
LDN193189 was dissolved in citric acid – sodium citrate buffer solution pH=3.1 at a final 
concentration of 6.25 mg/ml. Mice were injected with 1x106 PyMT cells intravenously, 
and treated daily with an intraperitoneal (IP) dose of 35 mg/kg LDN193189 from day 5 to 
12 post tumor cells IV injection.  
 
6. Histology 
.6.1 Lung immunofluorescence   
Immunofluorescence to assess in vivo niche activation was performed in 4% PFA fixed, 
paraffin embedded lungs. 4 μm thick lung sections were cut, deparaffinised and 
rehydrated using standard methods. After antigen retrieval with citrate buffer, sections 
were stained with DAPI, an anti-GFP antibody to label tumor cells and either SMA to 
detect activated fibroblasts, or endomucin to detect endothelial cells (antibodies 
description and working concentrations in Table S4). Sections were mounted with Sudan 
Black B (SBS) to quench background auto-fluorescence. 
Images were acquired in an upright Zeiss LSM780 confocal microscope. Quantitative 
analysis of images was performed manually counting the number of SMA+ or 
Endomucin+ cells in direct contact with the GFP-labeled tumor cells in the tissue.   
 
.6.2 Immunohistochemistry (IHC-P) 
Tumors were fixed in 4% PFA for 24h and then embedded in paraffin blocks. 4μm thick 
tumor sections were cut, deparaffinised and rehydrated using standard methods. After 
antigen retrieval, sections were stained with Hematoxylin and Eosin (H&E) solution, or 
alternatively with DAPI and antibodies against Endomucin (endothelial cells) and/or Ki67 
(proliferating cells). 
Images were acquired in an upright Nikon Eclipse Ni-U light microscope.  
 
7. Lentivirus  
.7.1 Lentiviral constructs generation 
All lentiviral vectors used in this study were generated using Gateway® technology (Life 
Technologies).  
The lentivirus constructs expressing short hairpin RNAs (shRNAs) were obtained in a 
two-step approach: first, the shRNA paired primers were designed with XhoI, BglII 
restriction sites on the edges to be cloned into a Gateway pENTR plasmid under the H1 
promoter (attL1_H1promoter_cloning-site_attL2). Second, we performed a Gateway LR 
recombination between the pENTR plasmid containing the shRNA and the lentiviral 
vector p4300 (cPPT_CMVenh_attR_hPGK_EGFP_WPRE).  
 The lentiviral vectors expressing protein-coding DNA sequences were obtained by 
Gateway LR recombination between a pDONR plasmid containing the DNA coding 
sequence and a pDEST lentiviral backbone. For THBS2 overexpression, we engineered 
a lentiviral reporter construct excising the mouse Thbs2 cDNA sequence with EcoRI 
(Addgene plasmid 12411; pcDNA3_mTSP2) and inserting it into a gateway pENTR. The 
generated pENTR was subsequently recombined with a pDEST lentiviral backbone that 
drives Thbs2 gene expression under a mouse PGK promoter. The lentiviral backbone 
contains as well a truncated isoform of the human CD2 receptor (hCD2) and a Venus 
reporter gene. For a mild AXL expression, we recombined the pDONR plasmid 
containing the DNA coding sequence of Axl gene of human origin (Addgene plasmid 
23945; pDONR223_AXLORF) with a pDEST lentiviral backbone that only has the 
lentivirus LTR driving regions and a CMV enhancer. The lentiviral backbone contains as 
well an EGFP reporter gene. 
In Table S2 are the detailed descriptions of the expression constructs used in this study. 
To generate the lentiviral vectors expressing shRNAs, we used hairpin oligomers with 
the target sequences shown in Table S3: ‘shRNA sequences’. The shTHBS2 validated 
target sequences were taken from the website of Sigma Mission in collaboration with the 
RNAi consortium (TRC) scientist (http://www.sigmaaldrich.com/life-science/functional-
genomics-and-rnai/shrna.html). The target sequence for shAXL was described 
previously (Gjerdrum et al., 2010). All these sequences do not match any cDNA 
sequence of the corresponding specie (mouse) registered in BLAST other than that of 
their own target gene. 
 
.7.2 Lentivirus production 
Third-generation VSV-G pseudo-typed high titre lenti-viruses were generated by 
transient co-transfection of 293T cells with a four-plasmid combination as follows: One 
10 cm dish containing 1x106 293T cells was transfected using 2M CaCl2, and 2x HBS 
(51558, Sigma) with 15 µg lentiviral vector, 6 µg pMD2-VSVG, 6 µg pRSV-rev and 6 µg 
pMDL-g/p-RRE. Fresh media was added 24h after transfection. Supernatants containing 
lentiviral particles were collected 48h and 72h hours after transfection, and concentrated 
by ultracentrifugation at 22,000 RPM.  
 
.7.3 Primary cells lentiviral infections 
For lentiviral transduction, 105 primary PyMT cells/well were seeded in 6-well tissue 
culture dish and infected with EGFP or Venus concentrated reporter lentiviruses added 
in suspension using 10 μg/ml Polybrene (107689, Sigma). After 48 hours cells were 
trypsinized and successfully transduced cells were FACS sorted according to their 
EGFP/Venus expression. 
 
8. Cell culture 
.8.1 Culture conditions and reagents 
The human mammary carcinoma cell line MDA-MB-231 and the mouse carcinoma 4T1 
cell line were obtained from the Cell services unit at The Francis Crick Institute, and 
maintained in standard 2D culture conditions in DMEM with 10% FCS at 37C and 5% 
CO2.  
 Mouse mammary carcinoma primary PyMT cells were seeded 2D in plates coated with 
collagen-I coating solution (100 mg/ml BSA, 1M HEPES, 1:100 PureCol (5005-B, 
Advanced BioMatrix) in HBSS), and maintained in MEM media (DMEM/F12 
supplemented with 2% FCS, 10μg/ml Insulin (I9278, Sigma), 20ng/ml EGF (PHG0313, 
Invitrogen) and 1:50 L-Glutamax (35050-061, Life Technologies), and grown at 37C and 
5% CO2 after isolation from late stage MMTV-PyMT derived carcinomas. 
 
Mouse primary lung fibroblasts were isolated from a single-cell suspension of lung tissue 
that was depleted from Ter119+ red blood cells, immune CD45+ cells and endothelial 
CD31+ cells by MACS sorting. The remaining fraction was cultured overnight on plastic 
in DMEM with 10% FCS. Unless otherwise specified, all fibroblast experiments were 
performed on cells seeded on the top of a thin layer of a 2:1 mixture of collagen I 
(354249; BD Biosciences) and Matrigel (354234; BD Biosciences) as described 
previously (Calvo et al., 2013).  
 
Fibroblast cell lines where obtained from the Sahai Laboratory. For generating the NLF3 
cell line, normal lung fibroblasts were isolated from healthy lungs of aGFP/FVB/n mice. 
Lung CAFs were isolated from metastatic lungs of MMTV-PyMT FVB/n mice, and the 
mCherry CAFs were isolated from primary MMTV-PyMT FVB/n tumors in carcinoma 
stage. All fibroblast cell lines were generated according to the published Bio-protocol 
e1097 (Calvo, F., Hooper, S. and Sahai, E. (2014). Isolation and Immortalization of 
Fibroblasts from Different Tumoral Stages. Bio-protocol 4(7): e1097), available at 
http://www.bio-protocol.org/e1097. Briefly, tissue pieces are placed into dishes where 
they are compressed under a 20 mm coverslip in DMEM media under sterile conditions. 
After 7 days, fibroblasts have come out of the tissue into the coverslip and the dish and 
can be trypsinased with Trypsin/EDTA and transferred into a new dish. Once they reach 
80% confluency, primary fibroblasts are immortalized by infection with pBABE-HPV-E6-
puromycin retroviruses. Positively infected fibroblasts are selected by addition of 
puromycin (2 µg/ml final concentration) in the complete culture media for 7-10 days, 
when resistant clones expressing HPV-E6 (i.e. immortalized cell lines) are visible.  
 
.8.2 In vitro drug treatments 
R428 (1946, Axon MedChem) in vitro treatment was performed as previously described 
(Holland et al., 2010). Briefly, PyMT primary cells plated 2D were treated with either 
vehicle (DMSO) or 1.5 μM R428 for 3 hours before washing and adding fresh media. 24 
hours after in vitro assays were performed. MDA231 cells were treated with 3 μM R428. 
Next day in vitro assays were performed. 
 
LDN193189 was dissolved in DMSO to 10 mM and use at a final concentration of 1 μM 
in the cell culture media. A single treatment was used as experiments were done over 24 
- 48h. 
 
.8.3 CAF-conditioned media 
To assess the effects of CAF-derived soluble factors on tumor cells with the specific 
BMP inhibitor LDN193189 (Figure 6L-M), CAFs were plated to reach confluency the day 
after in fresh DMEM with 10% FCS (as described in the 8.1). DMEM with 10% FCS, or 
24h CAF conditioned media was collected and concentrated 4x using Millipore 
Centriprep® 10K Centrifugal Filter Concentrators (Millipore, MIL4304). The concentrated 
media was used to treat PyMT tumor cells plated in collagen-I coated dishes for 24h, 
supplemented with 1μm LDN193189 and then either western blot analysis or 
immunofluorescence for ID1 was performed (antibody details and working concentration 
can be found in Table S4). 
 
9. Tumor sphere assay 
Cells prepared as a single-cell suspension were plated in Ultra Low Attachment 96-well 
plates (Constar) with Sphere Media (DMEM/F12 supplemented with 1:50 B27 
(Invitrogen), 20ng/ml EGF (PHG0313, Invitrogen), 20ng/ml FGF (PHG0026, Invitrogen), 
4mg/ml heparin (H3393, Sigma)), and kept at 37C and 5% CO2.  
PyMT primary cell spheres were established from total tumor cell preparations. After 
tumor dissociation, cells were plated on collagen overnight; trypsinazed and 104 cells/ 
200ul per well were seeded. Only the characteristic hollow spheres formed by these 
cells were quantified as tumor-spheres. 
For passaging, tumor-spheres were collected by centrifugation and dissociated both 
enzymatically by trypsin treatment (for 10 min at 37 °C) and mechanically by using 25G 
needles, and the resulting single-cell suspension was counted and re-plated at the 
original density. 
Quantitative analysis of images was performed using ImageJ software, and the Sphere 
Formation Index (SFI) was calculated considering both, number and size of the spheres, 
and was obtained by summing the area of all spheres formed divided by the number of 
single cells initially plated. 
 
10.   Western blotting 
CD24+AXL+ cells were FACS sorted and cultured in collagen-I coated dishes overnight 
(as in 8.1) and incubated for 24h with the pertinent media and treatments. Protein 
lysates were obtained after cell lysis with RIPA buffer (50mM Tris-HCl, 1% NP-40, 0.5% 
Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 50 mM NaF) supplemented 
with Roche cOmplete protease inhibitors cocktail tablets following standard procedures. 
Protein lysates were run in 12% polyacrylamide gels and blotted into AmershamTM 
Polyvinyllidine difluoride membranes (10-6000-29). Membranes blocking and antibody 
staining were performed in 5% BSA/PBS.  Antibody description and working 
concentration used can be found in Table S4. 
 
11.   BrdU proliferation assay 
Cancer cells proliferation rate was assessed measuring their nuclear BrdU incorporation 
after culturing them for 3 hours in 30 μM BrdU supplemented media (as in 8.1). Then, 
cells were washed with PBS, trypsinazed, fixed with 70% ethanol for 20 mins, 
permeabilized with 2N HCl, 0.5% TritonX-100 for 30 mins, and treated with 0.1M 
tetraboric acid for 2 mins. After washing twice with FACS buffer and cells were stained 
with anti-BrdU antibody (Table S4). 
 
12.   ELISA 
To measured THBS2 secretion, tumor cells were plated in adherent conditions (as in 
8.1) at a cell density of 50,000 cells per 100 μl. The resulting conditioned-culture media 
was collected 24h after plating and frozen at -80C. 
To quantify the levels of secreted protein in the conditioned-media, we used two different 
sandwich-ELISA kits, THBS2 ELISA Kit (SED822Mu, Cloud-Clone Corp) and Mouse 
THBS2 ELISA Kit (MBS942662, MyBioSource), and proceed according to the 
manufacturer’s protocols. The resulting colorimetric reaction was measured at 450nm 
using an automated ELISA plate reader (SpectreMax 190 Microplate Reader, Molecular 
Devices). 
 
13.   Flow cytometry 
.13.1 FACS analysis 
Flow cytometry analyses were carried out on a BD LSR-Fortessa system (BD 
Biosciences), and Propidium Iodide (PI) was used as a viability dye unless otherwise 
indicated.  
To examine the relationship between MICs, AXL and SCA1 in primary PyMT cells, PyMT 
tumors were dissociated and plated overnight on collagen-I coated dishes. Next day, 
cells were trypsinazed and stained for CD24 as an epithelial marker in combination with 
SCA1, AXL and CD90 in MACS buffer (0.5% BSA and 1mM EDTA in PBS). Antibody 
description and working dilutions can be found in Table S4. 
To assess AXL expression in metastatic lungs containing GFP labeled cancer cells, the 
tissue was dissociated and prepared as a single cell suspension as previously described 
(Malanchi et al., 2012). Subsequently, it was stained for lineage negative markers 
(CD31, CD45 and Ter119), CD24, CD90 (when expression was targeted to MICs) and 
mAXL-biotin or hAXL in MACS buffer. Antibody description and working dilutions can be 
found in Table S4. 
The expression of different protein assessed by FACS in MDA231 cell line was done 
after trypsinization of cultured cells (as in 8.1) and staining with the pertinent antibodies 
in MACS buffer.  
 
Differences in extravasation to the lungs by R428-treated or untreated PyMT cells was 
assessed by perfusing the lungs with PBS to flush out the blood, and then the clean 
tissue was dissociated in single-cell suspension and the number of GFP+ MICs or 
nonMICs (according to CD24/CD90 expression as in 13.1) present in the lungs were 
quantified. 
 
.13.2 Cell sorting 
All cell-sorting experiments were carried out on either a BD Influx or FACSAria cell sorter 
systems (BD bioscience). 
To sort the MICs from PyMT primary tumors or lungs containing GFP labeled cancer 
cells we used the staining indicated above (13.1). CD24+AXL+ and CD24+AXL- cells 
were sorted from primary PyMT tumor single-cell preparations plated overnight. The 
staining protocol previously described (Malanchi et al., 2011), was adapted and a mAXL-
biotinylated antibody was incorporated and conjugated to streptavidine-PEcy7 (Life 
Bioscience, 25-4317-82) (antibody description and working dilutions can be found in 
Table S4). 
EGFP+ or Venus+ cells expressing the lentiviral constructs were trypsinazed, washed 
with MACS buffer and sort according to the expression of the reporter gene. 
 
.13.3 ImageStream analysis 
Image stream analyses were carried out in an ImageStream®X Mark II Imaging Flow 
Cytometer (Amnis-Millipore). 
 
For whole lung analysis, cells were dissociated into a single cells suspension and 
depleted by MACS sorting from lineage negative cells (Ter119, CD45 and CD31). Next, 
the remaining fraction was stained with a live/dead fixable Near-Infrared dye (Invitrogen, 
L10119) and after fixed with 2% PFA for 30 mins and permeabilized with 0.1% Trinton-X 
for 10 mins. Next, cells were resuspended in FACS buffer (2% FCS in PBS) and stained 
with primary antibodies against Twist1, pSMAD1-5, ID1 or pSMAD2-3 at 4C overnight 
(antibody description and working dilutions can be found in Table S4). Subsequently, 
cells were washed twice in MACs buffer (0.5% BSA and 1mM EDTA in PBS) and 
incubated for 45 mins with secondary antibodies at room temperature. DAPI was added 
at 0.5 μg/ml to cells before analysis for nuclear staining. Tumor cells were identified by 
GFP expression.  
 
In vitro, ImageStream analysis of non-labeled MICs co-cultured with NLF3 for 4-5 days 
(as specified in the scheme in Figure 2E) was performed from a single cell suspension 
after gel digestion. NLF3 were excluded by GFP expression, and MICS were analyzed 
for Twist1 expression changes (Figure 6D-E). 
 
The acquired data was analyzed using Amnis IDEA management software to 
compensate for multi-color spectral overlap; plot and graphical gating of the cells as well 
as obtaining representative images of cells.  
 
14. Immunofluorescence 
All cancer cell immunofluorescence microscopy was performed on cells seeded on 
glass-bottom 35 mm MatTek dish (P35-1.5-14-C, MatTek) or glass coverslips coated 
(Thermo Scientific) with collagen solution (Cell culture procedure). Samples were fixed 
with 4% PFA for 10 min, permeabilized with 0.5% TritonX-100 for 30 min and 0.1% 
TritonX-100 for 20 min. Samples were blocked for 45 min at room temperature in 
blocking solution: 4% BSA in PBS with 0.05% Tween20 (Sigma). Then, cells were 
incubated with primary antibody in blocking solution overnight at 4 C. After 3 washes of 5 
min in PBS, secondary antibody in blocking solution was added. After 3 washes of 5 min 
in PBS, samples were mounted using Dako Fluorescent Mounting Media (S3023, Dako), 
and analyzed using either upright or inverted Zeiss LSM710. 
Quantitative analysis of images was performed using Imaris 7.6.4. Tumor cells were 
identified using an automated threshold based on GFP expression or a homogenous cell 
body staining. The mean intensity of E-Cadherin, AXL and Vimentin was then measured. 
 All fibroblast immunofluorescence, unless stated otherwise, were performed on cells 
seeded on the top of a thin layer of a mixture of 2:1 collagen-I:Matrigel as described 
previously (Calvo et al., 2013). Briefly, after 24h on the gel and the pertinent treatments, 
cells were fixed in 4% paraformaldehyde for 1 h. Cells were permeabilized by incubation 
in PBS 0.5% NP-40 (Sigma) at 4C for 20 min, in PBS with 0.3% Triton X-100 (Sigma) at 
room temperature for 20 min and in PBS with 0.1% Triton X-100 at room temperature for 
15 min. Samples were blocked for 60 min at room temperature in blocking solution: 4% 
BSA in PBS with 0.05% Tween20 (Sigma). Then, cells were incubated with primary 
antibody in blocking solution in a wet chamber overnight at 4C. After 3 washes of 15 min 
in PBS, secondary antibody in blocking solution was added. After 3 washes of 15 min in 
PBS, samples were mounted and analyzed using an inverted Zeiss LSM710. 
Quantitative analysis of images of CAF markers was performed using Imaris 7.6.4. To 
quantify FAP, fibroblasts were identified using an automated threshold based on their 
GFP expression. The mean intensity of FAP was then measured. 
 
Antibody description and working dilutions can be found in Table S4. 
 
15.   Live cell imaging 
For two dimensional image acquisition cells were plated sub-confluent into 24-well glass 
bottom MatTek plates (P24G-1.5-10F, MatTek) coated with collagen solution. Once 
attached, cells were kept in the microscope chamber at 37C and 5% CO2 and images 
were acquired every 5 mins for 12 hours. The acquired digital images were merged 
using MetaMorph Automation and Imaging Analysis Software (Molecular Devices Inc.). 
Cell tracking speed analysis was performed using Mathematica 8.0 (Wolfram). 
 
16.   Fibroblasts and tumor cells co-cultures 
Experimental set up 1 (Figure 2E). To assess fibroblast activation via the induction of 
different activation markers over 24h, GFP labeled NLF3 cells were seeded on top of a 
layer of 2:1 collagen-I:Matrigel mix in a 35-mm glass-bottom MatTek dish (P35-1.5-14-C, 
MatTek), together with tumor cells in a 1:3 fibroblast:tumor cells ratio. Normally on 100 μl 
of gel mix, 1.5x104 GFP NLF3 cells were seeded with 4.5x104 sorted MICs/nonMICs. 
The co-culture was maintained in MEM media (DMEM/F12 supplemented with 2% FCS, 
10μg/ml Insulin (I9278, Sigma), 20ng/ml EGF (PHG0313, Invitrogen) and 1:50 L-
Glutamax (35050-061, Life Technologies).  
 
The same experimental setting was used to evaluate the impact of activated NLF3 on 
MICs mesenchymal inhibition (Figure 6D-E). In this case, to ensure NLF3 full activation 
the co-cultures were incubated 3-5 days before analysis, and tumor cells were examined 
by flow cytometry for AXL expression or by ImageStream for Twist1 expression.  
 
Experimental set up 2 (Figure 2I): To assess fibroblast activation via their ability to 
remodel an extracellular matrix, normal primary lung fibroblasts or the NLF3 cell line 
were embedded in 100 μl of 2:1 collagen-I:Matrigel and seeded on a 35-mm glass-
bottom MatTek dish (P35-1.5-14-C, MatTek). Once the gel was set, we introduced a low 
height co-culture insert (PICM-ORG-50, Millipore) where tumor cells were seeded in a 
1:3 fibroblast:tumor cells ratio. The co-culture was maintained in MEM media 
(DMEM/F12 supplemented with 2% FCS, 10μg/ml Insulin (I9278, Sigma), 20ng/ml EGF 
(PHG0313, Invitrogen) and 1:50 L-Glutamax (35050-061, Life Technologies). Unless 
stated otherwise, the gel contraction value refers to the contraction observed after 3 
days, obtained by comparing the relative diameters of the well and the gel using ImageJ 
software, and the contraction was calculated as the gel area relative to the well area in 
arbitrary units (A.U.). 
 
Experimental set up 3 (Figure S6D): To assess the effect of fully converted CAFs over 
the phenotypic mesenchymal features of cancer cells, sorted MICs were plated 
overnight in collagen-I coated 35-mm glass-bottom MatTek dish (P35-1.5-14-C, 
MatTek). Next day, we introduced a low height co-culture insert (PICM-ORG-50, 
Millipore) were CAFs were seeded in a 3:1 fibroblast:tumor cells ratio for 24h. The co-
culture was maintained in MEM media (DMEM/F12 supplemented with 2% FCS, 
10μg/ml Insulin (I9278, Sigma), 20ng/ml EGF (PHG0313, Invitrogen) and 1:50 L-
Glutamax (35050-061, Life Technologies). 
 
17.   3D spheroids assays 
.17.1 Mixed spheroids invasion assay 
GFP+ MICs were freshly isolated from an actin-GFP MMTV-PyMT mouse and GFP- 
nonMICs were isolated from unlabeled MMTV-PyMT mice by cell sorting according to 
their CD24/CD90 expression (see 13.1). 
Next, GFP+ MICs and GFP- nonMICs were re-aggregated in ultra-low attachment 
conditions overnight in 1:9 ratio, in line with their relative distribution in primary tumors in 
vivo. The micro-spheroids formed were embedded in: pure collagen-I BD Biosciences 
cat. no. 354249), a 2:1 mixture of collagen-I and Matrigel (BD Biosciences cat. no. 
354234), yielding a final collagen-I concentration of ~4.6 mg/ml and a final Matrigel 
concentration of ~2.2 mg/ml. Micro-spheroids were allowed to invade for 48 hours before 
fixation with 4% PFA and staining with Phalloidin-TRITC (Sigma P-1951) and DAPI. 
Spheroids were imaged using a Zeiss LSM780 confocal microscope and invasive cells 
quantified using Volocity 3D Image Analysis Software by PerkinElmer. 
 
.17.2 Spheroids-CAFs invasion assay 
FACS sorted GFP+ MICs or nonMICs were re-suspended in DMEM with 10% FBS and 
0.2% methyl cellulose at 2.5 x 105 cells/ml with or without 2.5 x 104 mCherry labeled 
PyMT-CAF. Spheroids were formed by hanging drop assay overnight and then 
embedded in 2:1 collagen-I:Matrigel mix. Spheroids were allowed to invade for 48 hours 
before fixation with 4% PFA, followed by DAPI staining. Spheroids were imaged using a 
Zeiss LSM780 confocal microscope and invasive cells quantified using Volocity 3D 
Image Analysis Software by PerkinElmer. 
 
.17.3 Organoid assay in Matrigel 
A single cell suspension of FACS sorted MICs was pre-treated with R428 (as specified 
in 8.2) and then directly seeded in pure Matrigel and maintain in Sphere Media 
(DMEM/F12 supplemented with 1:50 B27 (Invitrogen), 20ng/ml EGF (PHG0313, 
Invitrogen), 20ng/ml FGF (PHG0026, Invitrogen), 4mg/ml heparin (H3393, Sigma)) at 
37C and 5% CO2 for 10 days. After 3 days cells are grouped into clusters. Quantitative 
analysis of images was performed 10 days after seeding using ImageJ software. The 
Organoids Formation Index (OFI) was determined considering both, number and size of 
the organoids, and was obtained by summing the area of all organoids formed divided 
by the number of single cells initially plated. 
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